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Gamma-secretase (GS) is a multi-protein, aspartyl protease complex consisting 
of presenilin (PS1), nicastrin (NCT), anterior pharynx-defective-1 (APH-1) and 
presenilin enhancer 2 (PEN-2)1,2. GS cleaves a variety of substrates, all of which are 
type I transmembrane proteins. The activity of GS has been most extensively studied 
in relation to the processing of amyloid precursor protein (APP) and Notch due to their 
implication in Alzheimer’s disease and cancer respectively. The role of GS in these 
pathways makes the enzyme an attractive drug target; however, a major obstacle of 
using GS as a pharmacological target to treat these diseases is the development of 
specific inhibitors that selectively target the cleavage of only one substrate. In the case 
of APP processing, an ideal pharmaceutical would not only conserve cleavage of other 
gamma-secretase substrates, but would also maintain production of non-
amyloidogenic amyloid beta (Aβ) peptides.  
 
In an effort to discover novel GS modulators we have developed and utilized 
an efficient in vitro gamma-secretase activity assay that can be used to measure GS 
activity on both Notch and APP concurrently. We have shown that recombinant 
substrates of gamma-secretase compete for cleavage in our assay and that measured 
IC50 values are significantly different when determined in the presence of an additional 
substrate. This work demonstrates the importance of using accurate biochemical 
assays when calculating selectivity margins. 
 
We have utilized this assay to study novel gamma-secretase inhibitors and 
modulators, specifically, benzimidazoles which inhibit Notch processing while 
simultaneously altering APP cleavage specificity. The data presented herein suggest 
that similar to their mechanism of proton pump inhibition, benzimidazoles modulate 
gamma-secretase activity by binding to cysteine residues on Notch, PS1-NTF, PS1-
CTF, and Pen-2.  
 
A large portion of the evidence for benzimidazole binding to GS and Notch 
consists of protein labeling experiments performed with benzimidazole based probes. 
In addition to using these probes for target identification, we have also undergone a 
systematic comparison of available copper-free click chemistries. We have validated 
the use of molecular probes for target ID by showing direct labeling of the known 
benzimidazole target, the gastric proton pump, and have identified several novel 
binding partners of benzimidazole compounds.  
 
 
 
 
 
 
iii 
 
BIOGRAPHICAL SKETCH 
 
Chelsea Paresi was born in Salt Lake City, Utah in 1988. After graduating 
from Olympus High School, she remained in Utah, attending Westminster College on 
a Presidential Scholarship, awarded for her previous academic success. During her 
time at Westminster she earned the Eccles Scholarship from 2007 to 2011, the Gore 
Math & Science Scholarship from 2008 to 2009, and the Alumni Association 
Scholarship from 2009 to 2011.  Chelsea was on the Dean’s Honor Roll each of her 
four years at Westminster and was awarded the “Outstanding Student in Chemistry” 
award upon graduating in 2011.  
 
Chelsea has always had a strong interest in pharmacological sciences. She 
received her Pharmacy Technician Certificate during high school and intended on 
going to Pharmacy school after college. As such, she majored in Chemistry, but 
quickly realized a passion for research. She completed a summer fellowship at 
University of California (UCSD) in 2009, where she screened a large library of 
compounds for inhibition or activation of PH domain and Leucine rich repeat Protein 
Phosphatase (PHLPP).  In her junior and senior year she worked as a laboratory 
assistant in a small start-up called Electronic BioSciences; there she executed research 
aiming to develop state of the art, nanopore based systems for DNA sequencing, 
chemical detection and research and development applications. She performed single 
ion-channel studies, measuring the variance in conductance as a single strand of DNA 
passes through wild type and mutant forms of the  biological pore, alpha-hemolysin. 
iv 
 
Chelsea graduated summa cud laude from Westminster College with a B.S. in 
Chemistry in May 2011.  
 
 That summer Chelsea traveled with her future husband and two dogs across the 
country to New York City, where she entered the Pharmacology program of Weill 
Cornell Graduate School of Medical Sciences and was a recipient of the “Vincent du 
Vigneaud First-Year Poster Presentation Award.” In spring 2012, she joined the lab of 
Dr. Yue-Ming Li at Memorial Sloan Kettering Cancer Center and began her thesis 
work. Chelsea was the recipient of an NIH T32 Pharmacology training grant from 
2012-2014. She presented her work at annual Pharmacology retreats and student 
research symposiums. Her graduate career culminated in a first author paper in 
Molecular BioSystems detailing the use of copper-free click chemistry for target 
identification with covalent probes, in addition to two other first-author publications 
currently in preparation.  
 
 Chelsea was an active member in the graduate school community, serving for 
two years as the executive council’s careers chairperson, spearheading an initiative to 
educate graduate students on alternative career paths, and chairing a committee to plan 
and execute a yearlong seminar series.  
 
 
 
 
 
 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my son, Jameson and his grandma, my mom, Shelley.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
ACKNOWLEDGEMENTS 
 
 It feels very surreal to be finally writing my thesis. There were more times than 
I can count where I thought about giving up along the way, and I have so many people 
to thank for continually supporting and motivating me to keep going.  
 
 First, I’d like to thank my mentor, Dr. Yue-Ming Li. He is a brilliant scientist, 
an understanding boss and overall a really wonderful human being. He truly cares 
about the lab and his students, which has resulted in an unusually pleasant work 
environment. He has taught me to be a critical thinker, an expert pharmacologist and 
to always perform a proper triplicate. Yue-Ming was practically always available to 
discuss results, practice presentations, trouble-shoot protocols, or come into the lab 
and fix it himself when something was really broken. I’d also like to extend a huge 
thank you to my committee members for their time commitment and constructive 
criticism: Dr. Minkui Luo, Dr. Steven Gross, Dr. Lonny Levin and Dr. Xuejen Jiang. I 
also want to express my deepest appreciation to our secretary, Pascale Presendor, who 
keeps our lab running and our members happy.  
 
I’m incredibly grateful to the entire Pharmacology Department at Weill 
Cornell, for an outstanding and well-rounded education and never ending support for 
its students. I want to thank the past and present members of the Li Lab for making lab 
somewhere I truly enjoyed being.  I am constantly amazed at the compassionate and 
collaborative spirit of our lab. In particular, I want to thank Courtney Carroll, Danica 
Chiu, Alissa Brandes, Natalya Gertsik, Christina Crump, Deming Chau, Feng Weng, 
Qi Liu, Wenbo Pei. These people are extraordinarily intelligent and excellent 
vii 
 
scientists. They have each been teachers and mentors in their own right, and I so 
appreciate their friendship.  
 
 Lastly, and certainly not least, I need to thank my friends and family. I have 
been unbelievably blessed to have an unfailing support system over the past five years. 
I would not be in New York, in a graduate program today without my husband, 
Thomas, helping me to realize my own potential, teaching me to always strive for 
more and constantly loving and supporting me. My friends, Courtney, Danica, Emily, 
Sara, Mandy, Suzanne, Jenny, Rachel, Laura and Jeff have made the past five years 
some of the best of my life and have continually taken such great care of me and my 
little family, I don’t know what I would have done without them. Most importantly, I 
want to thank my family, my Dad, Jeff, my aunts Lulu and Becky and especially my 
mom, for being an unwavering source of love and support my entire life. My mom’s 
compassion, altruistic spirit and her own battle with cancer have inspired me to spend 
my life striving to help others, and although she isn’t here today, I would not be who I 
am today without her.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
TABLE OF CONTENTS 
 
 
BIOGRAPHICAL SKETCH......................................................................................iii 
DEDICATION...............................................................................................................v 
ACKNOWLEDGEMENTS........................................................................................vi 
TABLE OF CONTENTS..........................................................................................viii 
LIST OF FIGURES......................................................................................................x 
LIST OF TABLES......................................................................................................xii 
LIST OF ABBREVIATIONS...................................................................................xiii 
LIST OF SYMBOLS..................................................................................................xv 
 
 
CHAPTER 1: Introduction..........................................................................................1 
1.1 Gamma-Secretase and Regulated Intramembrane Proteolysis.................................1 
1.2 The Gamma-Secretase Complex...............................................................................1 
1.3 Gamma-Secretase Regulation and Substrate Specificity..........................................6 
1.4 Alzheimer’s Disease and the Amyloid Cascade Hypothesis....................................8 
1.5 The Notch Signaling Pathway.................................................................................11 
1.6 Gamma-Secretase as a Therapeutic Target.............................................................15   
1.7 Hypothesis and Thesis Overview............................................................................23 
 
 
CHAPTER 2: Materials and Overview of General Methodologies...........................25 
2.1 Materials..................................................................................................................25 
2.2 Expression and Purification of Recombinant Substrates........................................26 
2.3 Membrane Preparation............................................................................................27 
2.4 In Vitro Gamma-Secretase Activity Assay.............................................................27 
2.5 Cell-Based Gamma-Secretase Activity Assay........................................................28 
2.4 Photoaffinity labeling (PAL) with PPI-BP probes followed by WB analysis.......29 
2.5 Direct labeling with tetrazine probes followed by fluorescence gel-scanning......31 
 
 
CHAPTER 3: Discovering Novel Gamma-Secretase Modulators-  
Development of One-Pot In Vitro Gamma-Secretase Activity Assay........................33 
3.1 Background.............................................................................................................33 
3.2 Results.....................................................................................................................36 
3.3 Discussion and Conclusions....................................................................................47 
 
 
CHAPTER 4: Benzimidazoles are Novel Gamma-Secretase Modulators.................49 
4.1 Background.............................................................................................................49 
4.2 Results.....................................................................................................................52 
4.3 Discussion and Conclusions....................................................................................65 
 
ix 
 
 
CHAPTER 5: Benzimidazole Covalent Probes and the Gastric H+/K+-ATPase as a 
Model System for Protein Labeling in a Copper-free Setting....................................69 
5.1 Background.............................................................................................................69 
5.2 Results.....................................................................................................................71 
5.3 Discussion and Conclusions...................................................................................79 
5.4 Detailed Methods....................................................................................................80 
 
 
CHAPTER 6: Thesis Summary and Major Implications..........................................88 
 
 
APPENDIX A: Preliminary LC-MS Analysis of Benzimidazole-Notch Adduct Formation..94 
APPENDIX B: SPECS compound screen...................................................................98 
APPENDIX C: GSI-34 Optimization........................................................................107 
 
CHAPTER 7: References………………………………………………………….109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
 
CHAPTER 1 
Figure 1.1: The gamma-secretase complex……………………………………………2 
Figure 1.2:  Gamma-secretase cleavage of APP……………………………………...10     
Figure 1.3: The Notch signaling pathway…………………………………………….13 
Figure 1.4: Chemical structures of select gamma-secretase inhibitors……………….16 
Figure 1.5: Chemical structures of “typical” gamma-secretase modulators………….18 
Figure 1.6: Structurally diverse GSIs and GSMs bind to presenilin on distinct ……..20 
Figure 1.7: Chemical structures of gamma-secretase inhibitors in clinical trials…….22 
 
CHAPTER 3 
Figure 3.1: Schematic of In Vitro Gamma-secretase activity assay………………….35 
Figure 3.2: One-pot assay optimization………………………………………………37 
Figure 3.3: rNotch and rAPP compete for cleavage by gamma-secretase……………39 
Figure 3.4: Model of substrate competition for cleavage by gamma-secretase………40 
Figure 3.5: Kinetic analysis of substrate cleavage in the one-pot assay……………...41 
Figure 3.6: Using the one-pot AlphaLISA assay to screen numerous compounds ….42 
Figure 3.7: Chemical structure of L-685,458 and one-pot vs. two-pot IC50 curves….43 
Figure 3.8: Chemical structure of LY-450139 and one-pot vs. two-pot IC50 curves...44 
Figure 3.9: Chemical structure of GSM-1 and one-pot vs. two-pot IC50 curves……..46 
Figure 3.10: Chemical structure of GSM-25 and one-pot vs. two-pot IC50 curves…..46 
Figure 3.11: Chemical structure of BMS-708,163 and one-pot vs. two-pot IC50 …..  47 
 
CHAPTER 4 
Figure 4.1 Chemical structures of proton pump inhibitors…………………………...50 
Figure 4.2: Activation of substituted benzimidazoles under acidic conditions………50 
Figure 4.3: Benzimidazole compounds inhibit NICD production and increase Aβ….53 
Figure 4.4: Structure activity relationship analysis…………………………………...54 
Figure 4.5: Reducing agents abolish benzimidazole inhibition of Notch cleavage......55 
Figure 4.6: Rabeprazole is a non-competitive gamma-secretase inhibitor…………...56 
Figure 4.7: Schematic of the Notch substrate within the active site of GS…………..57 
Figure 4.8: P2 cysteine of rNotch is vital for inhibition by benzimidazoles………....58 
Figure 4.9: Production of AICD from mutant P2C APP is inhibited ..........................59 
Figure 4.10: Photoaffinity labeling with PPI-BP shows specific labeling ..................61 
Figure 4.11: Benzimidazole based tetrazine probe specifically labels.........................63 
Figure 4.12: TAMRA labeling with PPI-Tz.................................................................64 
Figure 4.13: P2C in recombinant substrates is specifically labeled by PPI-Tz ...........65 
Figure 4.14: TAMRA labeling of WT rNotch is increased with decreasing pH. ........66 
Figure 4.15: Benzimidazole compounds do not increase Aβ42 production when.......67 
 
CHAPTER 5 
Figure 5.1: Structures of synthesized benzimidazole probes .............................71 
Figure 5.2: Benzimidazole probes inhibit gastric H+/K+-ATPase activity.................73 
Figure 5.3: Benzimidazole probes label the gastric H+/K+-ATPase...........................75 
xi 
 
Figure 5.4: TAMRA labeling with Rabe-Tz.................................................................77 
 
APPENDIX A 
Figure A.1: Predicted m/z for benzimidazole-Notch peptide adduct............................94 
Figure A.2: LC-MS analysis of synthetic Notch1 peptide............................................95 
Figure A.3: LC-MS analysis of Rabeprazole incubated with synthetic Notch1...........96 
Figure A.4: LC-MS analysis of Rabeprazole................................................................97 
 
APPENDIX B 
Figure B.1: Lead compound in SPECS screen for Notch selective inhibitors..............98 
Figure B2: SPECS compounds tested in cell-based gamma-secretase assay.............106 
 
APPENDIX C 
Figure C.1: Cell based gamma-secretase activity assay with C21vs GSI-34.............107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF TABLES 
CHAPTER 1 
Table 1.1: Multiple roles of Notch signaling in solid tumors.......................................15 
 
CHAPTER 3 
Table 3.1: Summary of calculated kinetic parameters of one-pot assay.......................40 
 
CHAPTER 5 
Table 5.1: Proteins identified by MS analysis of Rabe-Tz pull down..........................78 
 
APPENDIX B 
Table B.1: Results of in vitro gamma-secretase assay for each SPECS compound.....99 
Table B.2: Chemical structures of screened SPECS compounds...............................102 
 
APPENDIX C 
Table C.1: Summary of in vitro gamma-secretase assay data for GSI-34 analogues.108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF ABBREVIATIONS 
 
αCTF: α-Secretase cleaved C terminal fragment of APP  
βCTF: β-Secretase cleaved C terminal fragment of APP  
AD: Alzheimer’s disease  
ADAM: A disintegrin and metalloproteinase  
AICD: APP intracellular domain  
ANPP8: HEK293 cells overexpressing 4 components of γ-secretase (Aph1, Nct, PS, 
Pen2)  
APH1: Anterior pharynx defective 1  
APOE: Apolipoprotein E  
APP: Amyloid precursor protein  
ATP4A: Gene encoding gastric H+/K+-ATPase 
Aβ: β-Amyloid peptide  
BACE-1/β-secretase: β-Site APP Cleaving Enzyme 1  
CHAPSO: 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate  
COX: cyclooxygenase  
CSL: CBF1/Su(H)/Lag-1, also known as RBP-Jκ family  
CuAAC: Copper(I)-catalyzed Azide-Alkyne Cycloaddition, also called Azide-Alkyne 
Huisgen Cycloaddition  
DMSO: Dimethyl sulfoxide  
EM: Electron microscopy  
ER: Endoplasmic reticulum  
FAD: Familial Alzheimer’s disease  
FLIM: Fluorescence-lifetime imaging microscopy  
GS: Gamma-secretase 
GSAP: Gamma-Secretase activating protein  
GSI: Gamma-Secretase inhibitor  
GSM: Gamma-Secretase modulator  
L458: L-685,458  
LY450139: Also called semagacestat  
MBP: Maltose binding protein  
NCT: Nicastrin  
NFT: Neurofibrillary tangles  
NICD: Notch intracellular domain  
Notch ΔE: Notch construct lacking extracellular domain 
NSAIDs: Non-steroidal anti-inflammatory drugsxi  
PBS: Phosphate buffered saline  
PEN2: Presenilin enhancer 2  
PMSF: Phenylmethanesulfonyl fluoride  
PPI: proton pump inhibitor 
PS: Presenilin  
PS1-CTF: Presenilin1 carboxy-terminal fragment  
PS1-NTF: Presenilin1 amino-terminal fragment  
PS-FL: Full length presenilin  
xiv 
 
PVDF: polyvinylidene difluoride  
RIP: Regulated intramembrane proteolysis  
RIPA: Radioimmunoprecipitation assay buffer  
sAPPα: Soluble APP, cleavage product of α-secretase  
sAPPβ: Soluble APP, cleavage product of β-secretase  
SAR: Structure-activity relationship  
SDS: Sodium dodecyl sulfate  
SDS-PAGE: SDS-polyacrylamide gel  
TAMRA: 5-carboxytetramethylrhodamine  
TBTA: Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine  
TCEP: Tris(2-carboxyethyl)phosphine hydrochloride  
TMD: Transmembrane domain  
UV: Ultra-violet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF SYMBOLS 
α: Alpha  
β: Beta  
γ: Gamma  
Δ: Delta  
ε: Epsilon  
κ: Kappa  
μ: Mu, for micro  
Å: Angstrom  
˚: Degree 
1 
 
CHAPTER 1: 
Introduction 
1.1 Gamma-Secretase and Regulated Intramembrane Proteolysis 
The term “Gamma-secretase” (GS) was first coined in 1993 to describe the 
cleavage of the Amyloid Precursor Protein (APP) within the transmembrane domain, 
generating the infamous beta-amyloid (Aβ) peptides that are deposited in the brains of 
Alzheimer disease (AD) patients[1]. While it would be at least a decade before the 
identity of  gamma-secretase was fully elucidated, this was one of the earliest reports 
of regulated intramembrane proteolysis (RIP) [2]. RIP is an evolutionarily conserved 
mechanism that involves coordination of a water molecule within the lipid membrane 
to hydrolyse a peptide bond of the membrane-anchored substrate [3, 4].  In the case of 
aspartyl proteases such as gamma-secretase, two aspartyl residues within the active 
site act as an acid and a base to activate a water molecule for nucleophilic attack on 
the carbonyl carbon of the substrate scissile bond[5]. Cleavage of gamma-secretase 
substrates results in the release of both extra- and intra-cellular peptide fragments that 
go on to transduce cellular signals in a variety of manners[6].  
 
1.2 The Gamma-Secretase Complex  
As a result of the culmination of years of extensive research, it is now well 
understood that gamma-secretase is a large complex comprised of four obligatory 
subunits: Presenilin (PS), Nicastrin (NCT), anterior pharynx-defective-1 (Aph-1) and 
presenilin enhancer 2 (Pen-2)[7, 8], all of which are necessary and sufficient for 
catalytic activity[9] and are present in a 1:1:1:1 stoichiometry [10] (Figure 1.1).  Each  
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Figure 1.1: The gamma-secretase complex. The gamma-secretase complex is 
formed by the assembly of Aph1 and Nicastrin to create an initial sub-complex 
scaffold. The catalytic core, presenilin, binds next, followed by Pen-2, which results in 
endoproteolysis of presenilin to generate NTF and CTF, activating the complex. The 
black stars represent the catalytic aspartate residues of presenilin.  
 
 
subunit is synthesized in the endoplasmic reticulum; NCT and APH-1 form an initial 
sub-complex scaffold, followed by binding of PS, then PEN-2[8]. Incorporation of 
PEN-2 results in rapid endoproteolysis of PS between transmembrane domains (TMD) 
6 and 7 into a C-terminal fragment (CTF) and N-terminal fragment (NTF)  that remain 
closely associated within the complex[11, 12].  Endoproteolysis generates a fully 
formed gamma-secretase that is trafficked through the Golgi to the plasma membrane. 
While the numerous mechanisms of gamma-secretase regulation will be discussed in 
the coming sections, it is important to note that the presence of a fully formed gamma-
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secretase complex does not necessarily mean the complex is catalytically active [13-
15].  
 
Presenilin 
The first identified subunit of gamma-secretase was presenilin. It was 
simultaneously discovered to be involved in both AD and embryonic development 
through two independent lines of research. Genetic analysis of Familial Alzheimer’s 
disease (FAD) patients revealed mutations in the previously uncharacterized genes 
presenilin 1 (PSEN1) [16, 17] and presenilin 2 (PSEN2) [18].  In the same year, the 
PSEN gene was also identified to regulate Notch in Caenorhabditis elegans, which is 
vital for cell signaling during development [19].  It was first observed that mutations 
in PS result in changes in the amount of Aβ peptides generated, as well as the ratio of 
the  longer, more aggregate prone peptide, Aβ42, to shorter peptides such as Aβ40[20-
25]. Classification of PS as the catalytic core of gamma-secretase did not occur until 
later, when knock out of PS1 was shown to significantly reduce the production of Aβ 
peptides in mouse neurons[26], and  deficiency of PS1 in mouse or Drosophila was 
shown to also reduce the proteolytic release of  the Notch intracellular domain  
(NICD) [27, 28].  A gamma-secretase inhibitor was shown to block both APP and 
Notch processing, further confirming that PS is the protease responsible for the 
cleavage of both substrates[27] .  Additional evidence that PS is an aspartyl protease 
and  the catalytic subunit of GS include: the finding that mutation of two conserved 
aspartate residues in PS1 and PS2 result in significantly reduced Aβ production[29, 
30],  aspartyl protease transition state analogs directly bind PS and inhibit gamma-
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secretase activity[31], and recombinant PS reconstituted into proteoliposomes is 
sufficient for substrate cleavage in the absence of other gamma-secretase subunits[12].   
 
Full length PS is approximately 50kDa and has 9 TMDs [32, 33]. The protein 
exists as two isoforms: PS1 and PS2. PS1 is not only more abundant, but also more 
active and possibly more amyloidogenic [34]. The catalytic aspartate residues in both 
homologs are located within TMD 6 and 7, at the interface of the NTF and CTF [35].   
While the identification of presenilin was a huge accomplishment in the field, it was 
immediately clear that it was not the only protein involved in gamma-secretase 
activity, as over-expression of PS is not sufficient to increase gamma-secretase 
activity[36].  
 
Nicastrin (NCT) 
Immunochemical purification using antibodies against PS identified Nicastrin, 
a 130kDa, heavily glycosylated, Type 1 integral membrane protein, as part of the 
gamma-secretase complex[37].  In addition to its function as a scaffold for the 
formation of the complete complex [38], NCT has also been found to play a role in 
complex stability and trafficking [8, 39, 40]. There is a large body of evidence 
showing that Nicastrin also plays a role in substrate docking and specificity [41-45]; 
however, contradictory reports have demonstrated NCT-independent gamma-secretase 
activity [46], suggesting it may not actually be required for substrate recognition.  
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Presenilin enhancer 2 (Pen-2) 
Pen-2 was discovered through a genetic screen in C. elegans looking to 
identify genes that modify PS activity on the Notch homologs, glp-1 and lin-1 [47]. 
Pen-2 is an approximately 12kDa protein that has been historically thought to be a 
“hairpin” like, two-transmembrane protein [47]. However, a recent report suggests the 
first hydrophobic domain may form a reentrant loop, while the second spans the 
bilayer. Knock down of Pen-2 not only drastically decreases gamma-secretase activity, 
but also decreases CTF and NTF levels, while increasing the stability of full length PS 
[48], suggesting Pen-2 plays an important role in the endoproteolysis of PS. Several 
groups have validated the requirement of Pen-2 for maturation of full length PS into 
NTF and CTF [12, 49].  Additionally, a catalytically active, endoproteolysis deficient 
mutant of presenilin, PS1ΔE9, was shown to have no activity when expressed in Pen-
2
-/- 
MEFs, suggesting that Pen-2 is still required outside of its function in 
endoproteolysis[50]. Interestingly, overexpression of Pen-2 shifts preference from PS1 
containing complexes to PS2 containing complexes, indicating a regulatory role for 
the subunit as well [51].  
 
Anterior pharynx-defective-1 (Aph-1) 
Also discovered in the C. elegans screen mentioned above was Aph-1[47, 52]. 
Aph-1 is an approximately 29kDa protein with seven TMDs [53].  Similar to 
Nicastrin, Aph-1 is involved in providing the initial scaffold for complex formation 
[53, 54] and also in substrate selectivity. While NCT is thought to be involved in 
substrate selection via direct binding, Aph-1 isoform-dependent substrate processing 
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has been observed [55].  Humans have two Aph-1 genes, Aph-1a and Apha-1b. Aph-
1a is alternatively spliced to give Aph-1aS or Aph-1aL [56]; taking the two presenilin 
homologs and a 1:1:1:1 stoichiometry into consideration this means there are 6 distinct 
gamma-secretase complexes that can be formed in the cell.  
 
1.3 Gamma-Secretase Regulation and Substrate Specificity 
In addition to processing APP and Notch, GS has been reported to process more 
than 90 substrates [57] (although many of these substrates have yet to be verified as 
physiologically relevant).  Among the numerous substrates, there is no consensus 
sequence, and the only apparent requirement is that the substrate be a Type 1 
membrane protein that has undergone ectodomain shedding [58].  To make matters 
more complicated, GS can cleave many of these substrates at multiple positions within 
the transmembrane domain. While it may appear that GS functions as a general 
“membrane proteasome”, the regulation of its activity is actually quite complex and, 
the signaling pathways involved are vital to cellular function.  The mechanisms that 
govern gamma-secretase regulation and substrate specificity are not fully understood, 
but clearly encompass a wide array of processes.   
 
The requirement for each of the subunits described above provides intrinsic 
regulation, based on their own spatial and temporal expression patterns. Additionally, 
the possible heterogeneity of each complex can also dictate the activity of the 
complex. As briefly mentioned above, Presenilin exists in two isoforms and Aph-1 in 
three, which are present in a mutually exclusive manner, meaning there are 6 possible 
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complex compositions. It has been shown that PS1 and PS2 expression levels vary 
between tissues and that deficiency of either causes distinct phenotypic differences 
[59]. In addition to differential substrate specificity, the two isoforms also exhibit 
differential product preference, as PS1-containing complexes have been shown to 
generate more Aβ42 [60].  Aph-1 can exist in the gamma-secretase complex as three 
different forms. Similarly to PS, Aph-1 has tissue specific expression patterns, and the 
isoforms have been reported to differ in their production of longer versus shorter Aβ 
peptides [55]. 
 
While not absolutely required for gamma-secretase activity, additional regulatory 
proteins such as hypoxia inducible factor 1-α (Hif1α) [61] and gamma-secretase 
activating protein (GSAP) [62, 63]  have been reported to directly bind to the gamma-
secretase complex and regulate its activity. There have also been reports of feedback 
regulation by the ecto-domain shedded APP substrate itself, which can bind directly to 
an allosteric site on gamma-secretase to modulate Aβ production [64]. 
 
Several lines of evidence suggest that gamma-secretase contains a substrate 
“docking” site that is physically separate from the active site. Gamma-secretase can 
simultaneously bind to substrate and a transition state analogue inhibitor [65, 66],  
these transition state analogues show non-competitive inhibition [67, 68], and FRET 
analysis has shown close proximity of the APP substrate and Presenilin when PS is 
bound to a transition state inhibitor[69]. The exact location of the docking site and the 
possible existence of multiple docking sites is still unclear, but the available evidence 
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suggests that the large ectodomain of Nicastrin positions the substrate into a docking 
site located on Presenilin, approximately three amino acids from the active site[70].  
The substrate then may either translocate through the membrane into the active site, or 
“kinks” to present the scissile bond to the catalytic aspartates.  
 
Controlled intracellular trafficking of APP can influence the cleavage products of 
processing by GS, while Notch is predominantly processed at the plasma membrane 
[71-74]. Exciting recent studies have also shown that PS1 and PS2 are differentially 
trafficked within the cell, and that PS2 containing complexes localized to late 
endosomes/lysosomes generating a prominent pool of intracellular Aβ primarily 
comprised of the longer more aggregate prone species [75]. Lipid composition may 
also play an important role in GS regulation, as cholesterol has been repeatedly 
implicated in the production of Aβ and Alzheimer’s disease, as it can affect trafficking 
of APP in lipid rafts. This is thought to sequester the necessary components for 
signaling into close proximity [76, 77].  
 
1.4  Alzheimer’s Disease and the Amyloid Cascade Hypothesis 
Alzheimer’s disease is a global health crisis characterized by diminished cognitive 
function, memory loss and eventual inability to perform daily tasks and execute bodily 
functions. Alzheimer’s disease is irreversible and has no cure.  More than 5 million 
Americans are currently living with AD. Treating dementia patients cost more than 
$236 billion dollars in 2015 alone, and with a large aging population, those numbers 
are expected to rise exponentially in the coming years (Alzheimer’s Association 
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2015).  Autosomal dominant inheritance of mutations in either PSEN or APP causes 
early onset and familial AD [78], and the body of evidence implicating Aβ in sporadic 
AD is quickly growing. Therefore, a solid understanding of gamma-secretase cleavage 
of APP is vital to understanding the underlying mechanisms of this debilitating 
disease. 
 
While the exact pathological mechanism of AD is not fully elucidated, it is 
generally believed that accumulation of Aβ peptides drives a sequence of pathogenic 
events that ultimately lead to dementia [79]. The physiological function of APP 
processing is not completely understood, but is thought to play a role in neuronal and 
synaptic processes. On the contrary, the mechanism of processing has been generally 
elucidated due to its pathological consequences (Figure 2).  APP is cleaved in two 
separate pathways involving GS and at multiple positions within its TMD. In the 
amyloidogenic pathway, GS cleavage of APP following ectodomain shedding by beta-
secretase (BACE) leads to release of sAPPβ and ultimately to the production of 
amyloid beta (Aβ) peptides of various lengths and the APP intracellular domain 
(AICD) [80].  Recent studies suggest that APP is cleaved in a sequential manner, 
removing 3-4 amino acids at a time, and yielding two possible product lines depending 
on the initiating cleavage site [81, 82]. However, contradictory studies have been 
published [83-85] . In the non-amyloidogenic pathway, the ectodomain of APP is shed 
by α-secretase which results in the production of P3, sAPPα and AICD and precludes 
the formation of Aβ peptides [86, 87].  
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Figure 1.2: Gamma-Secretase cleavage of APP. The amyloid precursor protein 
(APP) can be cleaved in two separate pathways. In the non-amyloidogenic pathways 
(shown to the left) α-secretase cleaves APP to release sAPPα, resulting in cleavage by 
GS to generate p3 and AICD. In the amyloidogenic pathway (shown to the right), APP 
is first cleaved by β-secretase to generate βCTF, followed by sequential GS cleavage 
to yield AICD and Aβ peptides of various lengths.  The starting cleavage site, either 
amino acid 48 or 49, dictates the end product, either Aβ38/42 or Aβ37/40. (Figure 
adapted from Carroll et. al. Brain. Res. Bull. 2016) 
  
It is the longer, more hydrophobic and aggregate prone peptides, such as Aβ42, 
that are thought to be the more “toxic” species of the Aβ peptides. Aβ42 is the more 
abundant species found in brain plaques [88]  and a higher ratio of Aβ42:Aβ40 has 
been found to increase the toxicity and  aggregation potential for total Aβ [89].Not 
surprisingly, many of the reported FAD mutations result in an increase in Aβ42, and 
all presenilin FAD mutations result in an increase in the ratio of Aβ42: Aβ40 [78], 
which correlates more closely to the age of onset of FAD than total Aβ [90]. In 
addition to the direct genetic link between gamma-secretase processing of APP and 
FAD, extensive research suggests that this mechanism is involved in early onset and 
sporadic AD as well. All AD patients exhibit Aβ deposition in brain regions serving 
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memory and cognition, and Aβ42 oligomers isolated from  late-onset AD brains 
decrease synapse density, inhibit long-term potentiation, and enhance long-term 
synaptic depression in the rodent hippocampus [79]. A protective mutation in APP has 
been identified and shown to decrease the production and aggregation of Aβ peptides 
[91]. Additionally, the only identified major risk factor for AD, APOE4, has been 
shown to contribute to excess Aβ aggregation by decreasing its clearance from the 
brain [92-94].  
 
1.5 The Notch Signaling Pathway 
The Notch gene was discovered 97 years ago, with the observation that 
haploinsufficiency results in notches at the wing margin of Drosophila melanogaster 
[95]. Nearly a century later, it is now recognized that Notch plays a fundamental role 
in cell-fate determination.  Notch dictates vital cell processes such as differentiation, 
proliferation and apoptosis in developing and adult tissues in organisms from sea 
urchin to humans [96] [97]. 
 
The Notch family of receptors includes four paralogues (Notch 1-4)  [98] that are 
all type 1 transmembrane proteins of approximately 300kDa [96].  Notch proteins are 
synthesized as a precursor that is cleaved by a furin-like convertase (S1 cleavage) to 
generate a mature, calcium dependent, non-covalent heterodimer [99].  Although the 
Notch signaling pathway is recognized to be extraordinarily complex and not 
completely understood, a general mechanism for canonical Notch signaling is widely 
accepted (Figure 1.3) [97]. Ligands of the Delta-Serrate-Lag2 (DSL) family (in 
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mammals these include Jagged (JAG) 1,2 and Delta-Ligand Like (DLL) 1,3 and 4) 
expressed on an adjacent cell can bind to the Notch receptor, resulting in a 
conformational change that exposes the S2 cleavage site to the  metalloproteinase 
tumor necrosis factor-α-converting enzyme (TACE; also known as ADAM17). S2 
cleavage allows for further processing by gamma-secretase at the S3 site and 
subsequent release of the Notch intracellular domain (NICD).  NICD travels to the 
nucleus, converting CBF1-Su(H)-lag1 (CSL) from a repressor complex to an 
activating complex, which recruits other co-activating proteins, such as mastermind-
like 1(MAML1), to regulate the transcription of target genes [100]. The accessory 
transcription factors present in each cellular context dictate the outcome of signaling 
in different cell types. Some of the most well characterized Notch target genes include 
the basic-helix-loop-helix (bHLH) transcriptional repressors hairy enhancer of split 
(HES) and the hairy-related transcription factor (HRT or HEY), cyclin D1 and MYC 
[100, 101].  Notch target genes subsequently regulate the expression of genes involved 
in cell-fate determination such as differentiation, proliferation, stem-cell maintenance 
and self-renewal and apoptosis (Figure 1.3).   
 
Although the core components of Notch signaling are ubiquitous, the 
environmental context of Notch signaling dictates the outcome, such that the cell 
exerts multiple levels of regulation.  Spatial and temporal expression of ligand and 
receptor is vital, as Notch signaling is extremely sensitive to gene dosage.  
Additionally, biosynthesis, post-translation modifications, trafficking and degradation 
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of core components or accessory modifiers can also influence the role Notch signaling 
plays in a cell [100].   
 
Figure 1.3: The Notch signaling pathway. Ligands of the DSL family expressed on 
adjacent cells bind the extracellular domain (E.D.) of the Notch receptor resulting in 
sequential cleavage by TACE and GS to release the Notch Intracellular domain 
(NICD), which travels to the nucleus to cooperate with other transcription factors and 
regulates expression of target genes.  
 
Consistent with its pivotal role in determining cell-fate, Notch pathway 
perturbations are implicated in numerous disease states, including genetic disorders 
and cancer. The first reports of oncogenic Notch were identified in T-cell acute 
lymphoblastic leukemia (T-ALL), where chromosomal translocation involving Notch 
results in constitutively active NICD signaling [102]. It was later discovered that more 
than 50% of human T-ALL’s have activating mutations in the Notch locus. These 
mutations also cause constitutive activation of NICD involving ligand independent 
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signaling and/or impaired proteasome degradation of NICD [103]. To date, oncogenic 
Notch has been reported in numerous lymphoid neoplasms such as Human multiple 
myeloma [104], acute myelogenous leukemia (AML) [105], and chronic lymphocytic 
leukemia (CLL) [106].  
 
While the role of Notch signaling in hematopoietic cancers is well established, 
the role of Notch in solid tumors is highly context dependent (Table 1). Notch has 
been implicated in breast, colon,  pancreas, prostate, central nervous system and skin 
cancers; acting as an oncogene in most, but as a tumor suppressor in others (Table 1). 
Unlike leukemias, deregulation of Notch signaling in solid tumors is rarely due to 
genetic alterations, but rather inappropriate activation through the loss of a negative 
regulator or deregulated expression of signaling components[107].  Not only is Notch 
oncogenicity tissue specific, it’s also been shown that Notch signaling during the early 
stages of tumorigenesis can prevent tumor growth, while Notch activation is required 
in later stages for tumor progression [108, 109].   
 
Whether aberrant signaling is caused by genetic or molecular alterations, they 
often lead to cancer by resulting in increased self-renewal and inhibition of cell 
differentiation [110]. Notch signaling has also been reported to play a role in the 
epithelial to mesenchymal transition (EMT), which results in decreased expression of 
adhesion molecules, allowing cells to transverse the extracellular matrix and migrate 
through the vasculature [111].  It may also contribute to cancer progression via cross-
talk with other important signaling pathways such as EGFR, RAS, and  MYC [107]. 
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Table 1.1: Multiple roles of Notch signaling in solid tumors. Adapted from Ranganathan, 
P. et. al., Nature Review Cancer 11, 3380351 (May 2011). 
 
 
1.6  Gamma-Secretase as a Therapeutic Target   
Targeting Gamma-Secretase for Treatment of Alzheimer’s disease  
Based on the pivotal role gamma-secretase plays in prime signaling pathways 
of both Alzheimer’s disease and cancer, small molecule inhibition of the protease has 
been extensively explored.  Multiple gamma-secretase inhibitors (GSI’s) have been 
reported, used to investigate gamma-secretase function and several even entered the 
clinic. Active site directed GSI’s, such as the hydroxyethylene dipeptide isostere, L-
685,458, have been extensively utilized in research laboratories and further developed 
into activity-based molecular probes for identification, localization and isolation of 
gamma-secretase components[31, 51, 64, 66, 112-118].  
 
While incredibly useful in the research laboratory, complete inhibition of 
gamma-secretase abolishes cleavage of all substrates, resulting in an array of 
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unwanted side effects when used in humans. These include increased risk of skin 
cancer due to inhibition of Notch signaling and worsening memory, as evident by the 
failed clinical trial for LY450139 (Semagacestat, Eli Lily) [119]).  In efforts to 
overcome these toxicities, the use of “Notch-sparing” compounds such as GSI-953 
(Begacestat, Wyeth [now Pfizer]) and BMS-708,163 (Avagacestat, Bristol-Myer 
Squibb) was proposed [120, 121].  However, Avagacestat has been shown in follow-
up studies to have very little selectivity for Aβ42 over Notch [122, 123], and showed 
major adverse side effects, including but not limited to gastrointestinal disruption, 
dermatologic complications and cognitive worsening [124]. A phase 1 clinical trial 
testing Begacestat was discontinued in 2010 for unknown reasons.  
Figure 1.4: Chemical structures of select gamma-secretase inhibitors. 
 
Not only does complete inhibition of gamma-secretase have unwanted effects 
due to nondiscriminatory inhibition of Notch processing, but it appears that non-
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selective inhibition of APP processing can be damaging in its own right.  In a 
physiological setting, APP processing has been shown to be important for various 
neuronal and synaptic functions [125].  Complete GS inhibition results in an 
accumulation of the direct substrate, APP βCTF, which appears to be neurotoxic at 
high concentrations [126], and it has also been found to impact total Aβ42:Aβ40 ratio 
[127].  
 
Reports of the subsequent cognitive worsening with GSI treatment in clinical 
trials have made it very clear that the ideal therapeutic candidate must not only protect 
Notch signaling function, but also conserve total Aβ production.  Such gamma-
secretase modulators (GSMs) were discovered when certain non-steroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen, indomethacin and sulindac sulfide 
were found to selectivity inhibit Aβ42 production while increasing Aβ38 production, 
thus maintaining total Aβ levels. Furthermore, these compounds do not inhibit Notch 
cleavage and function outside of their activity on cyclooxygenase (COX) [128].  
Unfortunately, due to poor brain penetration and low in vitro potency (Aβ42 
IC50>10μm), these compounds did not proceed into clinical trials (with the exception 
of R-flurbiprofen which did not achieve statistically significant outcomes in a Phase 
III clinical trial [129]). However, they demonstrate the promise of selective gamma-
secretase modulation and paved the way for the development of second generation 
GSM’s with more favorable profiles.  
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In an effort to increase potency and permeability of the blood brain barrier 
(BBB), second generation GSM’s were developed. These include compounds which 
can be classified into three categories: NSAID-derived carboxylic acid molecules, 
non-NSAID-derived heterocyclic chemotypes, and natural product-derived 
compounds [130]. 
Figure 1.5: Chemical structures of “typical” gamma-secretase modulators. 
 
GSM-1 exemplifies a typical 2
nd
 generation, acid GSM, as it reduces Aβ42 
production, promotes the generation of Aβ38 and has negligible effects on Aβ40, total 
Aβ, NICD or AICD [84]. Structure activity relationship studies have shown the 
carboxylic acid moiety is not only critical for modulatory activity, but the 
corresponding ester or amide compounds acts as an “inverse” GSM, increasing the 
level of Aβ42 production [131, 132].  
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The imidazole compound, E2012, exemplifies the non-NSAID-derived, 2
nd
 
generation GSMs, shifting cleavage site preference to decrease the production of both 
Aβ40 and Aβ42, and simultaneously increasing Aβ37 and Aβ38 [133, 134]. E2012 
entered clinical trials in 2006, but was halted in favor of the development of an 
improved compound, E2212, that is reported to be more potent and also has a wider 
safety margin, however no updates have been reported thus far (ClinicalTrials.gov 
identifier NCT01221259.)  
 
The binding site of 1
st
 generation GSMs remains elusive as contradictory 
models have been reported; these fall into three possibilities: GSM’s bind gamma-
secretase [13, 135, 136], GSM’s bind the APP substrate [137-139], or GSMs bind both 
gamma-secretase and APP [140, 141]. The relatively low potency of these compounds 
required high concentrations for many of these studies, likely resulting in the detection 
of unspecific interactions being mistaken for the true drug target.  However, 2
nd
 
generation GSM’s of all chemotypes have been shown by various groups to bind 
presenilin [142-147] and induce conformational changes in gamma-secretase ([117, 
118, 141, 145]. Furthermore, a series of elegant photolabeling experiments have also 
demonstrated that each class of 2
nd
 generation GSM occupies a distinct binding site on 
presenilin [117, 147].  
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Figure 1.6: Structurally diverse GSIs and GSMs bind to presenilin on distinct 
allosteric sites (Adapted from Crump et al. 2013). 
 
While critics of the amyloid cascade hypothesis often cite failure of GSI’s and 
GSM’s to treat AD in the clinic as evidence against the prevailing model, it is more 
likely that failure has been due  not only to unwanted side effects on other gamma-
secretase targets, but also to sub-optimal dosing regiments[148].  Furthermore, the 
continued success of active and passive immunotherapy for lowering amyloid in the 
clinic support the amyloid cascade hypothesis and validate the importance of targeting 
this pathway to treat AD[79].  
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Gamma-Secretase Inhibitors for Cancer Treatment 
The extreme toxicity observed with GSI’s in the clinic may not be acceptable 
for treatment of AD, where patients are likely to require extended dosing regiments, 
but the threshold of acceptable toxicity for cancer treatment is much higher.  The use 
of GSIs to repress cancer stem cell growth has been successful in an in vitro 
experimental setting [149], providing evidence that GSIs may represent a viable 
therapeutic strategy. As such, several compounds have entered the clinic and are at 
various stages in the drug development pipeline for cancer therapy.  
 
RO4929097 has been shown to decrease proliferation and impair the ability to 
form colonies in human primary melanoma cell lines and effect tumor formation and 
growth in human primary melanoma xenografts [150]. It demonstrates minimal single 
agent efficacy [151-153], but was found to be safely tolerated and achieve clinical 
benefit when used in combination with standard chemotherapies in several clinical 
trials [154-156]. Furthermore, RO4929097 significantly sensitized breast cancer stem 
cells to ionizing radiation in a pre-clinical model [157].  
 
MRK-0752 is an oral GSI that was reported to reduce stem cell sub 
populations in vitro and in human tissues from clinical trials [158]. The compound 
was shown to effectively modulate Notch signaling and exert anti-tumor activity in a 
Phase I study of patients with advance solid tumors [159]. It was also shown to be 
well-tolerated and effective in treating children with refractory or recurrent CNS 
malignancies; however, extreme gastrointestinal side effects were reported [160]. It is 
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currently being tested in several Phase I trials for breast cancer in combination with 
standard chemotherapies [161].  
 
Among other promising pre-clinical results [162], PF-03084014 was reported 
to selectively induce apoptosis in chronic lymphocytic leukemia cells bearing Notch 
mutations, while having relatively little effect on normal T cells or T cells from 
patients that do not carry Notch mutations [163],  mimicking “selective” Notch-target 
therapy. Interestingly, the toxicity of PF-03084014 has been found to be somewhat 
mild when compared to other agents in the same class [164]. PF-03084014 is currently 
in multiple ongoing Phase I and II trials alone and in combination with other therapies 
[161].  
Figure 1.7: Chemical structures of gamma-secretase inhibitors in clinical trials 
for cancer treatment   
 
While relative success has been achieved in the clinic thus far, there is still much 
work to be done. In order to maximize therapeutic effects and minimize toxicity, it 
will be beneficial to show tumor dependency on Notch activation and treat those 
cancers accordingly.  Moreover, based on the data thus far, the use of GSI’s in 
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combination with other therapies such as traditional chemotherapy or ionizing 
radiation will yield the most curative effect [162].  
 
1.7 Hypothesis and Thesis Overview 
It seems to be fully accepted in the Alzheimer’s disease field that therapeutically 
targeting gamma-secretase will ideally be achieved through the use of gamma-
secretase modulators. In the cancer field, however, treatment with pan GSI’s has 
prevailed. While the threshold of acceptable toxicity is much higher for cancer 
treatment, the development of GSMs demonstrates that this may not necessary.  
Notch-selective compounds have been reported in the literature, but there has been 
little intentional research for such compounds. We believe that the discovery and 
development of such compounds would provide an excellent therapeutic option for 
Notch dependent cancers.  
 
 In an effort to discover Notch-specific inhibitors of gamma-secretase we have 
developed and optimized a “one-pot”, in vitro, gamma-secretase activity assay that can 
be used to measure gamma-secretase cleavage of Notch and APP simultaneously. This 
assay allows for screening of large compound sets with more accurate selectivity 
calculations.  
 
Using our in vitro assay, we have discovered that substituted benzimidazole 
compounds, which are known proton pump inhibitors widely used for gastrointestinal 
issues, are also modulators of gamma-secretase activity. Benzimidazoles potently 
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inhibit NICD production and increase Aβ peptides. We hypothesize that 
benzimidazole compounds share a similar mechanism of action with proton pump 
inhibition, meaning that they form a disulfide bond with their molecular target.  
 
Because there is no crystal structure of γ-secretase, we have a limited 
understanding of where previously reported GSIs/GSMs bind and how the location of 
binding impacts the modulation profile. Additionally, whether the recent high 
resolution electron microscopy (EM) structure of γ-secretase [165]  illustrates an 
active enzyme complex is questionable. Due to this, alternative methods must be 
utilized in order to elucidate the targets of GSIs and GSMs. Labeling using 
photoaffinity probes has been extremely successful in the past, and we have applied 
these techniques to our studies. Additionally, because we are working with a covalent 
inhibitor, we can utilize various copper-free click chemistry techniques in conjunction 
with covalent probes.  
 
This work presents a novel assay for screening potential GSIs and GSMs, 
demonstrates a novel mechanism of action for Notch-specific inhibition and gamma-
secretase modulation and provides insight into the optimal conditions for labeling with 
covalent probes for target identification.   
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CHAPTER 2:  
Materials and Overview of General Methodologies 
2.1 Materials 
HeLa (S3) cell pellet (mid-log) for membrane preparation was purchased from 
Biovest. ANPP8 (HEK293 cells that overexpress PS1, Aph1, NCT, and Pen2) were a 
gift from Dr. Sangram Sisodia and were grown in-house for membrane preparation 
and use in labeling experiments. Fresh porcine stomachs were ordered from 
Innovative Research Inc. and used for collection of the gastric mucosa and subsequent 
membrane preparation and vesicle isolation.  Biotin-PEG2-azide for azide-alkyne 
cycloaddition was purchased from ChemPep. Streptavidin Plus UltraLink Resin was 
purchased from Pierce.  Trans-cyclooctene biotin and trans-cyclooctene-TAMRA 
were synthesized in house by Dr. Qi Liu. Protease Inhibitor cocktail was made in 
house from powders purchased from Sigma Aldrich and used at final concentrations as 
follows: 1 mM benzamidine, 2.9 μM leupeptin, 5 μM antipain, 100 μM EDTA, and 
100 μM phenylmethanesulfonyl fluoride (PMSF). The PiColorLock Gold Phosphate 
detection system was purchased from Innova Biosciences and used for ATPase 
activity assays.  Typhoon Trio Variable Mode Imager (GE Healthcare) was used for 
in-gel fluorescence scans. Western blots were developed either with film or scanned 
with Odyssey CLx from LI-COR.  
 
Primary antibodies for Western blot: anti-Aph1a 28-3600 was purchased from 
Invitrogen. Anti-PS1-CTF loop MAB 5232 was purchased from Millipore. Anti-Pen2 
18189 rabbit polyclonal was purchased from Abcam. Anti-PS1-NTF was provided by 
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Dr. Min-Tain Lai (Merck Research Laboratories). The antibody against Nicastrin was 
generated by immunizing rabbits with a peptide epitope. Anti-ATP4A (ab174293) was 
purchased from AbCam.  Secondary antibodies for Western blots scanned on Odyssey 
were purchased from LI-COR: IRDye 800 CW goat anti-rabbit and IRDye 680 RD 
goat anti-mouse. 
 
AlphaLISA detection reagents for γ-secretase activity assays including 
Streptavidin coated donor beads, anti-mouse acceptor beads, protein-A coated 
acceptor beads were purchased from Perkin Elmer. G2-10 conjugated acceptor beads 
were made in-house according to the protocol provided by Perkin Elmer. The Aβ42 
cleavage specific antibody 10-G3 was kindly provided as a gift from Douglas Johnson 
(Pfizer); the Aβ40 cleavage specific antibody G2-10 was a gift from Merck Research 
Labs; and the Notch1 intracellular domain cleavage specific antibody SM320 was 
generated by Deming Chau. AlphaLISA signal was detected with an EnVision 
multilabel plate reader (PerkinElmer). 
 
2.2 Expression and Purification of Recombinant Substrates 
Recombinant substrates were expressed and purified as previously reported [64, 
166]. Briefly, plasmids encoding for recombinant Notch (rNotch) and APP (rAPP) 
substrates, PIad16-rNotch-Avi or PIad16-rAPP-Avi, were separately co-transformed into 
BL21 (DE3) E.Coli with pACYC184, which encodes for biotin ligase (BirA). Bacteria 
were incubated at 37°C until growth reached 0.4-0.8 at A600, then recombinant substrate 
expression was induced by the addition of isopropyl 1-thio-β-D-galactopyransoide 
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(100μM) in the presence of 50μM biotin for 5 hrs at 20°C. To generate non-biotinylated 
substrates, the same protocol was followed in the absence of biotin during induction. Cells 
were pelleted and lysed by French press (Spectronic Instruments). The soluble fraction 
was isolated by centrifugation at 17,000g for 30min then subjected to amylose affinity 
chromatography, purifying target proteins via a maltose binding protein (MBP) tag 
present on both substrates. The MBP tag was removed by overnight thrombin treatment at 
16°C to generate biotinylated, recombinant proteins. Mutant substrates were generated 
using Agilent QuickChange Lightening mutagenesis kit, expressed and purified as 
described above.  
2.3 Membrane Preparation 
Gamma-secretase containing HeLa or ANPP membranes were prepared as 
previously reported [31, 112]. Frozen cells were resuspended in 1X MES buffer  (50mM 
MES, pH 6.0, 5 mM MgCl2, 5 mM CaCl2, 150 mM KCl) containing “complete” protease 
inhibitors, PI and PMSF, (Boehringer Mannheim, Gaithersburg, MA) and lysed by French 
Press (Spectronic Instruments). Cell debris and nuclei were removed by centrifugation at 
800g for 10min. Supernatants were collected and centrifuged at 100,000g for 60min. 
Pellets were resuspended in a minimal amount of 1X MES buffer and re-centrifuged at 
100,000g for 60min. The final pellet was suspended in MES buffer and stored at -80°C.   
2.4 In Vitro Gamma-Secretase Activity Assay 
 Gamma-secretase present in HeLa membrane is incubated with recombinant, 
biotinylated substrate (0.4μM rNotch, 1μM rAPP) in the presence of 0.25% CHAPSO and 
PIPES buffer (50mM PIPES, 150mM KCl, 5mM CaCl2, 5mM MgCl2, pH=7.0) for 3 
hours at 37C. In a “two-pot” assay, substrates are separately incubated with HeLa 
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membrane. In the “one-pot” assay format, both substrates are incubated with HeLa in the 
same reaction.  Afterwards, an antibody specific to the cleavage site is added in the 
presence of streptavidin-conjugated donor beads (40ug/mL in APP assays and 20ug/mL in 
Notch assays) and Protein A-conjugated acceptor beads (5ug/mL) and incubated at room 
temperature overnight. The AlphaLISA signal is measured the next day using an Envision 
plate reader (Perkin Elmer, Waltham MA).  A pan GS inhibitor is used to determine 
background and vehicle (DMSO) is used as a positive control. For IC50 assays, normalized 
AlphaLISA signals were converted to percent vehicle values and used to create dose-
response curves which were fitted to 3 parameter curves using GraphPad Prism version 6 
(GraphPad Software, San Diego, CA).   
 
2.5 Cell-Based Gamma-Secretase Activity Assay 
For the Aβ cell-based γ-secretase activity assays, 35,000 HEK-APP cells were 
seeded in DMEM-HG media in a 96 well plate in order to achieve a confluency of 
50% in 24 hrs, at which point cells were treated with desired compounds or vehicle 
(0.1% DMSO). Background signal is determined from a negative control sample with 
1 μM JC2 (Compound E racemate). After 24 hours of treatment, cells are 
approximately 80% confluent and 25 μL of media is removed for testing using the 
suggested protocol for the Aβ three-plex (4G8) Meso Scale Discovery kit.  
 
For the NICD cell-based γ-secretase activity assays, 35,000 HEK293-NΔE 
cells were seeded in DMEM-HG media in a 96 well plate in order to achieve a 
confluency of 50% in 24 hrs, at which point cells were treated with desired 
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compounds or vehicle (0.1% DMSO). Background signal is determined from a 
negative control sample with 1 μM JC2 (Compound E racemate). After 24 hours of 
treatment cells should be ~80% confluent, then aspirate media from cells and replace 
with 25μL ice cold lysis buffer (0.25 % CHAPSO in PBS with PI cocktail) and shake 
for 45min at 4C. Once cells are completely lysed, remove 5 μL lysate and add to 20 
μL of detection mix (0.6 μg/mL biotin-anti-Myc antibody, 0.2 μg/mL SM320 
antibody, 5 μg/mL protein A acceptor beads, 10 μg/mL streptavidin coated donor 
beads in assay buffer containing 50mM HEPEs pH 7.5, 150 mM NaCl, 0.1% BSA, 
0.1% (Tween-20) in a 384 well plate. Read plate on Envision the next day.  
 
2.4 Photoaffinity labeling (PAL) with PPI-BP probes in HeLa membrane 
followed by western blot analysis 
 
Clickable PPI based probes were incubated with 600-800 μg of HeLa cell 
membranes at 37 °C for 1 hr in the presence or absence of parent compound in 1 mL 
of PBS, and then UV irradiated at 350 nm for 45 min to crosslink the benzophenone 
probe to nearby proteins. The samples were then ultracentrifuged at 90,000 ×g and the 
pellets were resuspended with 200 μL PBS buffer by homogenization with the 
TissueLyser at 25 rps for 2 min (Qiagen). Proteins were labeled with biotin by using 
Cu2+ catalyzed azide alkyne cycloaddition (CuAAC) click chemistry with 1 mM 
CuSO4, 1 mM TCEP, 0.1 mM TBTA, 100 μM biotin-azide, in PBS with 5% t-
butanol, 2% DMSO, and shaking for 1 hr at 25 °C. The samples were then 
ultracentrifuged at 90,000 ×g to remove click chemistry reagents and the pellets were 
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again resuspended by homogenization and solubilized in 500 μL of RIPA buffer (50 
mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% NP40, 0.5% deoxycholate), followed 
by centrifugation at 12,000 rpm to remove particulate matter. The supernatant was 
added to 20 μL of streptavidin ultralink resin slurry, and incubated overnight at 4 °C. 
The streptavidin resin was washed 3 times by centrifugation at 0.5 ×g with 500 μL of 
RIPA buffer and then washed an additional time with Tris-Buffered Saline with 0.1% 
Tween-20. Biotinylated proteins were eluted by heating with 30 μL of 2X SDS sample 
buffer for 10 min at 70 °C. Then 25 μL of the eluent was loaded on to an SDS- PAGE 
gel for protein band separation and then transferred to PVDF membrane and blotted 
for target proteins with indicated primary antibodies. 
 
2.4 Direct labeling with tetrazine probes followed by western blot analysis 
HeLa membrane (800ug) or ANPP membrane (100 to 300ug) was incubated 
with Rabe-Tz in PBS for 1 hour at 37°C while shaking. After incubation, copper free 
click reactions were initiated by adding trans-cyclooctene-biotin (16μM) to conjugate 
a biotin to labeled proteins for pull down. Click reactions were allowed to proceed for 
1 hour at room temperature. Reactions were centrifuged at 90,000 x g for 40 min at 
4°C. Supernatants were aspirated, thus removing excess click reagents. The pellets 
were resuspended by homogenization with a TissueLyser (Qiagen) at 25 rps for 2 min 
and solubilized in RIPA buffer (50 mM Tris (pH= 8), 150 mM NaCl, 0.1% SDS, 1% 
NP40, 0.5% deoxycholate) then centrifuged at 12,000 rpm to remove particulate 
matter. To show specificity, 50mM DTT was added to select samples and incubated 
for 5 minutes at RT.  Streptavidin ultralink resin slurry (Pierce) was added to all 
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supernatants and incubated overnight at 4C. Streptavidin resins were washed 4 times 
by centrifugation at 0.5 x g followed by aspiration of supernatant and addition of 
500μL RIPA buffer. Labeled proteins were eluted by incubation with excess biotin 
(2mM) in 2X Laemmli sample buffer (BioRad) at 70°C for 10min. Eluates were 
loaded onto a precast 4–20% Criterion™ Tris-HCl gel (BioRad) for protein 
separation, transferred to a PVDF membrane and blotted for target proteins with 
indicated primary antibodies.  
2.5 Direct labeling with tetrazine probes followed by fluorescence gel-scanning 
For labeling of gamma-secretase components benzimidazole probe, Rabe-Tz 
(1μM), was incubated with ANPP membrane (50ug) in PBS for 1h at 37°C in the 
presence or absence of 50mM DTT. Targeted proteins were labeled with tetramethyl 
rhodamine via spontaneous reaction of trans-cyclooctene-TAMRA (16uM) and the 
tetrazine present on Rabe-Tz for 1 hr at room temperature in the dark. Labeled 
proteins were centrifuged at 9,000 x g for 40 min at 4°C and the supernatant removed. 
Protein pellets were resuspended in 45μL PBS using the TissueLyser for 2min at 
25rps, followed by the addition of 15μL 4x Laemmli Sample buffer (BioRad) which 
was solubilized for 5min at 15prs, then centrifuged at 13,000 rpm to remove 
particulate matter. Samples were heated for 10min at 70°C and then loaded onto an 
SDS-PAGE gel for band separation and scanned for fluorescent bands. The same gel 
was then immediately stained with Coomassie blue (BioRad) to compare the total 
amount of protein in each sample.  
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For labeling of recombinant substrates, Rabe-Tz (1μM) was incubated with 
either wild type or mutant substrate (1-5μM) in the presence and absence of 50mM 
DTT and brought to a total reaction volume of 20μL with buffer either PBS or glycine 
buffer. Targeted proteins were labeled with tetramethyl rhodamine via spontaneous 
reaction of trans-cyclooctene-TAMRA (16uM) and the tetrazine present on Rabe-Tz 
for 1 hr at room temperature in the dark. Dye-free Laemmli SDS sample buffer (6μL) 
was added to samples, mixed well, and heated for 10min at 70°C. Samples were 
loaded onto a 16% pre-cast Tricine gel for band separation and scanned for fluorescent 
bands. The same gel was later analyzed for total protein by using the Thermo 
SilverQuest silver staining kit.  
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CHAPTER 3: 
Discovering Novel Gamma-Secretase Modulators- 
Development of One-Pot In Vitro Gamma-Secretase Activity Assay 
 
 
3.1 Background 
The pivotal role of gamma-secretase in both Alzheimer’s Disease and cancer 
makes the enzyme an attractive drug target; however, a major obstacle of targeting GS 
to treat these diseases is the need for specific inhibitors that selectively target the 
cleavage of only one substrate[130, 167]. This is evident based on the failure of 
several GSIs in clinical trials for AD, which failed primarily due to cytotoxicity in the 
gastrointestinal tract and severe immunosuppression as a result of unwanted 
suppression of Notch signaling[168, 169], and possibly unknown side-effects on other 
gamma-secretase substrates. As such, there is a need to develop substrate specific 
inhibitors and modulators. To do so efficiently requires superior in vitro assays that 
can accurately detect the production of specific gamma-secretase cleavage products; 
for example, assays that can distinguish Aβ peptides of various lengths.  
 
Production of Aβ peptides is commonly measured using enzyme-linked 
immunosorbent assays (ELISA)[170-172], western blot with cleavage site specific 
antibodies[173, 174], or mass-spectrometry[13, 82] while NICD production is most 
often studied using western blot[173, 175], RT-PCR of target genes[176] or reporter 
systems[177-180]. In addition to being indirect measures of gamma-secretase enzyme 
activity, these methods are often multi-step, labor intensive processes which are 
relatively low through-put. Other reported methodologies include 
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electrochemiluminescence based detection [64, 112, 127, 181] , homogeneous time-
resolved fluorescence (HTFR)[182] and flow cytometry using xMAP [183], but these 
are much less common. 
 
Our lab has developed a superior in vitro gamma-secretase assay utilizing 
AlphaLISA technology to detect the generation of specific gamma-secretase products 
[142, 166, 184].  This assay uses cleavage site specific antibodies in conjunction with 
FRET based donor and acceptor beads. When the beads are brought into close 
proximity to one another, via interaction with either the cleavage site antibody or a 
recombinant biotin tag, excitation at 680nm can be used to transfer a singlet oxygen 
from donor to acceptor bead generating a luminescent signal (615nm) which can be 
measured and quantified (Figure 3.1A). This assay system is less time consuming than 
other available methods, easy to automate [185], and relatively inexpensive.   
 
However, in its current state, cleavage of each substrate is assayed individually 
using a “two-pot” format (Figure 3.1B). This requires additional time and reagents 
than if production of each species is assayed simultaneously. Using the two-pot assay 
as a platform, we have developed a “one-pot” assay that can be used to detect the 
products of both APP and Notch cleavage simultaneously (Figure 3.2B). Rather than 
separately incubating substrates with gamma-secretase containing membranes, 
recombinant Notch (rNotch) and recombinant APP (rAPP) are incubated in the same 
reaction vessel, followed by sample separation for product detection. Not only does 
this assay save time and reagents, but it also allows for evaluation of therapeutic 
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candidates in an environment more similar to in vivo, where multiple substrates are 
present, allowing for more accurate calculation of selectivity margins.  
 
Figure 3.1: Schematic of In Vitro Gamma-secretase activity assay. A) Schematic 
representation of AlphaLISA detection technology. Protein-A acceptor beads bind to 
cleavage site specific anti-bodies while streptavidin donor beads bind biotin at the 
opposite terminus of the protein. When the two beads are in close proximity, 
AlphaLISA signal is generated by excitation of the donor beads at 680nm, transfer of 
singlet oxygen to the acceptor bead and subsequent emission at 615nm. B). In the 
traditional “two-pot” AlphaLISA assay, each substrate is incubated with gamma-
secretase individually, then reactions are split for detection of individual products.  C) 
In the “one-pot” AlphaLISA assay both APP and Notch are incubated with gamma-
secretase in the same reaction vessel.  
 
 A cell-based method for detecting APP and Notch cleavage simultaneously 
has recently been reported, termed the “dual substrate assay”, and has already 
36 
 
illustrated an over-estimation of selectivity margins as a result of testing compounds 
for activity against APP and Notch processing separately[186]. They have 
demonstrated in several instances that selectivity was drastically reduced or 
completely eliminated when both substrates are present, providing a plausible 
explanation for why GSI’s and GSM’s have not been successful in the clinic to date. 
While cell-based assays are invaluable for testing if compounds have physiological 
activity, in vitro assays provide a faster means to screen a large number of compounds. 
Here, we have developed and implemented a one-pot in vitro assay for measuring 
gamma-secretase cleavage of Notch and APP simultaneously.  
 
3.2 Results 
One-Pot Assay Optimization 
We first wanted to optimize the conditions for our one-pot assay to maximize 
signal and reduce background.  To determine the optimal amount of CHAPSO-
solubilized GS to be added to the in vitro reaction, the amount of GS containing HeLa 
membrane was titrated and enzyme activity was assayed using the one-pot activity 
assay format.  Figure 3.2A shows a concentration dependent increase in the generation 
of each product up to 120μg/mL.  Next, we varied the length of time the enzyme is 
incubated with recombinant substrates between 2 and 4 hours.  At the end of each time 
point an aliquot of the reaction volume was removed and stored at 4C. After the last 
time point, detection reagents were added to all samples and product generation was 
quantified the next day and plotted as seen in Figure 3.2B.  Gamma-secretase cleavage 
of both substrates and at each position in rAPP increased over time up to 4 hours.    
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Lastly, the amount of streptavidin donor beads (SAD) added to the detection mix was 
varied between 10 and 40μg/mL (Figure 3.2C).  In order to remain in the dynamic, 
linear range of detection, 80μg HeLa membrane was incubated with recombinant 
substrates for 3 hours for all subsequent experiments. For the detection of Aβ 
products, 20μg/mL SAD was used and for the detection of NICD 10μg/mL SAD was 
used.  
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Figure 3.2: One-pot assay optimization. A) The amount of solubilized gamma-
secretase added to the assay was titrated by adding various concentrations of HeLa 
membrane to each reaction.  B) The time of the reaction was varied from 2 to 4 hours. 
C) The concentration of streptavidin donor beads (SAD) was titrated in the detection 
reaction.  The final parameters for subsequent experiments were chosen to be 
80ug/mL HeLa for each reaction, incubated for 3 hours using 40ug/mL streptavidin 
donor beads for detection of Aβ products and 20ug/mL for detection of NICD.  Data 
shown are means +/- SEM (n=3).  
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Substrate Characterization  
 
 While the topic of competition between endogenous APP and Notch for 
cleavage by gamma-secretase has been explored previously, results have been 
controversial [41, 187].  It was important for us to determine if our recombinant 
substrates compete for cleavage by gamma-secretase in our assay. To explore this 
issue, we titrated the amount of one recombinant substrate, while keeping the 
concentration of the other constant.  Both substrates were expressed without the 
addition of biotin and the non-biotinylated proteins were used as the variable substrate, 
so as to isolate the effects of enzyme competition without any interference based on 
competition for donor beads.  Previous work by Svedruzic et al. using a similar in 
vitro system has shown that the presence of a recombinant Notch construct, NotchΔE, 
can have either activating or inhibitory effects on AICD production depending on the 
concentration used[188]. Reminiscent of that, we observe a slight initial increase in 
gamma-secretase activity for all products other than Aβ42 at the lowest concentrations 
of alternate substrate, followed by a dose dependent decrease in activity at higher 
concentrations (Figure 3.3A).  
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Figure 3.3: rNotch and rAPP compete for cleavage by gamma-secretase. 
Competition was assayed by titrating the concentration of one non-biotinylated 
substrate while keeping the concentration of the other biotinylated substrate constant 
and assaying for the cleavage of that substrate. For NICD detection the concentration 
of rAPP was kept at 1μM. For Aβ detection the concentration of rNotch was 0.4μM 
 
 
Several lines of evidence suggest the existence of  a substrate docking site that 
is physically distinct from the active site and that gamma-secretase can bind and 
cleave multiple substrates per one catalytic turn over[67, 68, 189].  According to this 
model, the two substrates compete for cleavage only at sufficiently high 
concentrations (Figure 3.4).   
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Figure 3.4: Model of substrate competition for cleavage by gamma-secretase. 
(Adapted from Svedruzic et. al. PLoS One. 2012. 
 
In support of this model, kinetic analysis showed an approximate two-fold 
increase in Km for the one-pot assay compared to individual assays, but little to no 
change in Vmax or Kcat for all products, indicating that the addition of the alternate 
substrate affects binding, but does not affect catalytic efficiency.  
 
Table 3.1: Summary of calculated kinetic parameters of one-pot assay.
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Figure 3.5: Kinetic analysis of substrate cleavage in the one-pot assay was 
performed by titrating the concentration of one substrate while keeping the 
concentration of the other constant and assaying for the cleavage of the substrate being 
titrated. The kinetic parameters Km and Vmax were calculated using a non-linear curve 
fit with the Michaelis-Menten equation and compared between the one-pot assay with 
both substrates present and a control assay with only the substrate being assayed for 
cleavage present.  (N≥8).  
 
One-Pot AlphaLISA Assay Can Be Used to Screen GSMs and GSIs 
One of the most useful applications of our one-pot assay is in screening for 
novel gamma-secretase modulators and/or Notch-selective inhibitors.  For “proof-of-
concept” we aimed to show that our assay could be used to screen the activity of 
numerous compounds against each gamma-secretase product simultaneously in a 
quick and efficient manner. Using one 384-well opti-plate our one-pot assay was 
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prepared with 11 test compounds, plus vehicle for a positive control, and we assayed 
for the modulation of Aβ38, Aβ40, Aβ42 and NICD production simultaneously. As 
seen in Figure 3.6, one can generate a heat map of one-pot assay results to quickly 
screen for compounds with unique modulatory activity. At 1μM compound, the four 
GSI’s tested (JC2, L458, JC34 and GSI-139) were all shown to have equal potency for 
inhibition of all products, while gamma-secretase modulators from various classes 
such as NGP-555, E2012, GSM-067, GSM-1, and GSM 616 selectively inhibit Aβ42 
production while increasing Aβ38 and having little effect on NICD, and the inverse 
GSM, iGSM-893, has the opposite effect, drastically increasing Aβ42 production.  Not 
surprisingly, the reported “Notch-sparing” inhibitor BMS708-163, was found to have 
no selectivity towards any of the gamma-secretase products supporting previously 
reported data from our lab [123].  
  
Figure 3.6: Using the one-pot AlphaLISA assay to screen numerous 
compounds simultaneously. Each compound was tested at 1μM for gamma-secretase 
modulating activity and the results were graphed as a heat map based on percent 
activity remaining as compared to vehicle (DMSO).  
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Testing GSI and GSM IC50 in the One-Pot Assay    
Previous work has shown that the concentration of the APP substrate, as well 
as the presence of the Notch substrate in a cellular assay are sufficient to shift IC50 
values for several GSM’s[186, 190]. We directly compared IC50 calculations between 
the one-pot assay and a two-pot assay control for compounds representative of several 
chemotypes.   
L-685,458 (L458) is a peptide based, transition-state mimic, which directly 
targets the active site to halt cleavage of all substrates with equal potency[191].  No 
significant difference was observed in the IC50 between the one-pot and two-pot assay 
(Figure 3.7), consistent with findings in the equivalent cellular dual substrate assay 
[186].  
 
Figure 3.7: Chemical structure of L-685,458 and one-pot vs. two-pot IC50 curves. 
IC50 values are reported in nM.  
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Semagacestat (LY-450139) has been studied in numerous clinical trials testing 
multiple dosing regiments with little success due to unwanted toxicity [148, 192]. This 
is not surprising as Chavez et al. reported the compound to preferentially inhibit 
cleavage of Notch to produce NICD over the cleavage of APP to generate AICD, 
however, reported selectivity margins for this compound vary widely[122, 186, 192]. 
Similarly, we observe selectivity for NICD inhibition over Aβ peptides in our two-pot 
AlphaLISA assay (Figure 3.8). However, when we test this compound in our one-pot 
assay, we see a drop in selectivity from 0.16 fold to 1.3 fold, consistent with results 
reported by McKee et al. where they report 0.6 selectivity in their cellular, dual 
substrate system[186].  It appears that the inconsistency in selectivity margins reported 
for this compound could be due not only to differences in assay systems, but also to 
the presence and local concentration of additional substrates.   
 
Figure 3.8: Chemical structure of LY-450139 and one-pot vs. two-pot IC50 
curves. IC50 values are reported in nM.  
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In an effort to overcome the challenges faced with using traditional GSI’s in 
the clinic, two classes of gamma-secretase modulators (GSMs) have evolved. The first 
are NSAID derived, acid GSMs, typified by GSM-1 which has been reported to be 
more than 30 times selective for inhibiting Aβ42 production over Notch 
cleavage[145]. In our two-pot assay we observe 210 fold selectivity, however in the 
one-pot assay, we see a drastic drop in selectivity to only 54-fold, as well as a drop in 
selectivity for Aβ42 over Aβ40 (from ≈8x to ≈4x) and Aβ42 over Notch (from ≈400x 
to ≈40x), verifying previously reported shifts in IC50 values at higher concentration of 
substrate. The loss in selectivity is not due to a decrease in potency for Aβ42 
inhibition, but rather a result of increased potency in inhibiting the other production of 
the other species (Figure 3.9). Interestingly, this trend was not observed with the 
structurally distinct imidazole compound, GSM-25, where we saw little difference 
between the one-pot and two-pot assay (Figure 3.10), but was repeatable when tested 
with un-biotinylated substrates (data not shown).  It has been previously shown that 
GSM-1 has a binding site that is distinct from the binding site for imidazole GSMs 
[117, 147], which could explain why we do not see this phenomenon with GSM-25. 
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Figure 3.9: Chemical structure of GSM-1 and one-pot vs. two-pot IC50 curves. 
IC50 values are reported in μM.  
 
 
Figure 3.10: Chemical structure of GSM-25 and one-pot vs. two-pot IC50 curves. 
IC50 values are reported in μM.  
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Consistent with previous reports from our lab and others, we found that the 
supposed “Notch-Sparing” compound, BMS-708,163, has a mere two-fold selectivity 
for Aβ42 over Aβ40 or Notch when tested in our traditional assay [123], and the small 
window of selectivity is completely abolished when tested in our one-pot assay 
(Figure 3.11).  
 
Figure 3.11: Chemical structure of BMS-708,163 and one-pot vs. two-pot IC50 
curves. IC50 values are reported in nM.  
 
3.3 Discussion and Conclusions 
Gamma-secretase is a prime target for therapeutic intervention in both 
Alzheimer’s disease and cancer. However, because gamma-secretase has numerous 
substrates, there is a need for compounds that selectively inhibit the cleavage of one 
substrate over the other in order to minimize unwanted side-effects. We have 
developed an in vitro “one-pot” gamma-secretase activity assay that can be used to 
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measure the production of several Aβ species and NICD simultaneously, and provides 
an ideal platform for drug discovery.  We have optimized the concentrations of each 
component in the reaction in order to maximize signal strength and reduce background 
noise. We have evidence for direct competition between the rNotch and rAPP 
substrates for cleavage by GS in our assay, but have used analysis of enzyme kinetics 
to demonstrate that while the additional substrate may affect binding or docking, it 
does not affect catalytic turnover.  
As evident by the discrepancies we’ve observed in IC50 values between the 
one-pot and two-pot assays and with the failure of Semagacestat in clinical trials, it is 
clear that having accurate and efficient assays to determine potency and selectivity 
margins between APP and Notch is vital to the success of using GSIs or GSMs to treat 
patients in the clinic. Furthermore, maintaining the production of Aβ40 may be 
equally as important as maintaining Notch signaling [126], so the ability to 
simultaneously detect multiple Aβ species is also imperative.  Use of the one-pot in 
vitro assay has the potential to save not only time and money, but could also prevent 
patients in clinical trials from experiencing unnecessary harm.  
On a small scale, we have shown the utility of the one-pot assay to screen for 
drug candidates with ideal modulatory profiles.  We are particularly interested in 
further developing the assay to be used in high-throughput screens, similar to our 
recent report on a Notch HTS assay [185], but believe that the one-pot assay has 
countless applications for investigation of gamma-secretase.    
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CHAPTER 4: 
Benzimidazoles are Novel Gamma-Secretase Modulators 
4.1 Background 
 Gamma-secretase is a prime therapeutic target for both AD and cancer, but it is 
clear that using gamma-secretase modulators will be necessary to overcome unwanted 
side effects that are a result of the wide array of gamma-secretase substrates present in 
each cell.  While extensive research has been done to develop gamma-secretase 
modulators for treatment of Alzheimer’s disease, the pursuit of Notch-specific 
gamma-secretase inhibitors has been lacking. The compound LY-450,139, originally 
intended to be used for AD treatment but found to be Notch-selective [122], 
demonstrates the existence of such compounds but has not been used for this purpose. 
There are currently no other Notch-selective compounds reported. Although the 
threshold of toxicity may be higher for potential cancer therapeutics, this may not be 
necessary if Notch-selective inhibitors can be discovered, optimized and utilized on 
Notch addicted cancers.   
The traditional in vitro gamma-secretase activity assay commonly utilized in 
our lab [166] has been developed into a 384-well and 1536-well microtiter plate 
format that can be used as a high-throughput screen for novel gamma-secretase 
inhibitors and modulators [185].  During validation of this assay, several proton-pump 
inhibitors such as Lansoprazole, Omeprazole and Rabeprazole (Figure 4.1) were 
identified to specifically inhibit NICD over Aβ40 production and found to have IC50 
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values for Notch inhibition of 3μM, 2.5μM, and 1μM respectively. Additionally, they 
cause a modest increase in Aβ production, most potently Aβ42.  
Figure 4.1: Chemical structures of proton pump inhibitors identified in HTS for 
Notch-selective inhibitors of gamma-secretase 
  
Proton pump inhibitors (PPIs) are substituted 2-pyridylmethylsulfinyl 
benzimidazole compounds that require acid activation before binding to their intended 
molecular target, the proton pump, or gastric H+/K+-ATPase. PPIs are administered 
orally, and remain relatively inert until they reach the acidic environment of the 
parietal cell where they are protonated, undergo spontaneous rearrangement to active 
sulfenamide and sulfenic acid derivatives, and  react with accessible cysteine residues 
in the proton pump to form a disulfide bond, irreversibly inactivating the enzyme[193, 
194] (Figure 4.2). Extensive research has verified this mechanism and shown that PPIs 
can react with several cysteine residues in the proton pump, but binding of any 
benzimidazole to Cys- 813 is sufficient to inhibit ATPase activity [195]. 
Benzimidazoles with high reactivity and activation rates, such as lansoprazole and 
omeprazole, generally bind Cys-813 exclusively, while slowly activated 
benzimidazoles such as pantoprazole are able to reach and inactivate less accessible 
cysteines as well [196].  
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 Figure 4.2: Activation of substituted benzimidazoles under acidic 
conditions to react with cysteine residues in the gastric proton pump.  
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Based on the known mechanism of action of PPIs and the proton pump, we 
hypothesized that benzimidazole compounds share a similar mechanism of action in 
inhibiting gamma-secretase cleavage of Notch.  In this study, we show several lines of 
evidence suggesting that benzimidazoles do in fact undergo a similar activation 
reaction and form a disulfide bond with a cysteine residue near the scissile bond of the 
Notch substrate, as well as bind to cysteines in NTF, CTF, and PEN-2.  These results 
represent a novel mechanism of action for gamma-secretase modulation and while 
selective inhibition of NICD is promising as a cancer treatment strategy, the potential 
for benzimidazoles is dampened by the observed increase in Aβ peptides. This data 
may shed light on recent findings that PPIs may not be as safe as originally assumed 
and should be taken into consideration before administering PPIs to patients.  
 
4.2 Results 
The Effect of Benzimidazole Treatment on Gamma-Secretase Activity in Biochemical 
and Cell-Based Assays 
 Figure 4.3A shows a prototypical benzimidazole compounds and the effect on 
in vitro gamma-secretase activity in our one-pot assay (Figure 4.3B). The IC50 for 
Notch cleavage is just under 1μM and we observe a slight increase in the production 
of Aβ peptides, most pronounced for Aβ42.  HEK293 cells stably expressing the NΔE 
Notch construct (which lacks the extra-cellular domain and does not require ligand 
binding for signaling) were treated with vehicle, GSI, or benzimidazole compound for 
24 hours, lysed and NICD levels were assayed using our AlphaLISA activity assay. 
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HEK293 cells stably overexpressing APP were treated similarly and Meso Scale 
Discovery (MSD) Aβ peptide kit was used to measure Aβ production in the media. 
Similar to our in vitro data, we observe a dose-dependent increase in Aβ peptides and 
a dose-dependent decrease in NICD (Figure 4.3D). Interestingly, Lansoprazole and 
Omeprazole have been previously reported to enhance amyloid beta production in cell 
models and transgenic mice [197], but researchers did not postulate on the mechanism 
of action.   
Figure 4.3: Benzimidazole compounds inhibit NICD production and increase Aβ 
peptides. A) Chemical structure of prototypical benzimidazole compound used in our 
studies.  B) In Vitro , one-pot gamma-secretase activity assay shows IC50 for NICD 
production of less than 1uM and modest increase in Aβ production. C) Cell-based 
assay for Aβ detection demonstrates dose-dependent increases in each peptide with 
increasing concentrations of benzimidazole compound. D) Cell-based assay for NICD 
production shows dose-dependent decrease in NICD production with Rabeprazole and 
Lansoprazole treatment. *Cell-based NICD assay was performed by Dr. Deming Chau 
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Structure-Activity Relationship Analysis 
Our working hypothesis is that benzimidazoles are modulating gamma-secretase 
through a mechanism similar to inhibition of the proton pump. The first step in 
benzimidazole activation is protonation of the nitrogen on the pyridine ring (Figure 
4.2). Therefore, if these compounds are modulating gamma-secretase via a similar 
mechanism, removal of this nitrogen should impede inhibition of Notch cleavage. We 
have synthesized an analogue, PPI-benzene, and shown that it does not inhibit Notch 
cleavage (Figure 4.4B). Furthermore, the sulfoxide of PPIs rearranges to a 
sulfonamide during acid activation and analogues in which the sulfoxide moiety has 
been removed and replaced with either a sulfone or sulfoxide, also lose the ability to 
inhibit Notch cleavage (Figures 4.4C,D).   
Figure 4.4: Structure activity relationship analysis A) The standard benzimidazole 
compound is a potent inhibitor of NICD production. B) Removal of the pyridine 
nitrogen abolishes inhibitory activity. Changing the sulfoxide moiety to a sulfone C) 
or sulfide D) also results in loss of NICD inhibition. 
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Reducing Agents Prevent Benzimidazole Inhibition of Notch Cleavage 
Based on the above structure-activity relationship data, which suggests a 
similar mechanism of activation may be required for benzimidazole modulation of 
Gamma-Secretase activity, we next asked if disulfide bond formation was also 
involved. In order to test this, we added the reducing agent DTT to our Notch IC50 
assay and found that this resulted in loss of Notch inhibition (Figure 4.5A). 
Conversely, addition of DTT to an IC50 assay for the transition state mimic, L458, 
does not have any effect on inhibition. The same results were observed with other 
reducing agents such as TCEP (data not shown).  
Figure 4.5: Reducing agents abolish benzimidazole inhibition of Notch cleavage. 
A) The effect of 50Mm DTT on NICD IC50 B) 50mM DTT has no effect on inhibition 
of gamma-secretase by a pan GSI, such as the transition state mimic, L458.  
 
Enzyme Kinetics Demonstrate a Non-Competitive Mechanism of Action  
To investigate where benzimidazoles are binding to modulate gamma-
secretase, we first analyzed enzyme kinetics and found that Rabeprazole does not 
affect Km for Notch cleavage, but lowers Vmax  (Figure 4.6A). Further double-
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reciprocal plot shows intersection at the x-intercept, suggesting non-competitive 
inhibition through allosteric binding (Figure 4.6B).  This means that substrate binding 
to enzyme and inhibitor binding to enzyme is not mutually exclusive, and it is the 
formation of the enzyme-substrate-inhibitor complex that is catalytically inactive. 
  
Figure 4.6: Rabeprazole is a non-competitive gamma-secretase inhibitor.          A) 
Increasing concentrations of Rabeprazole results in decreased Vmax, but has no effect 
on Km. B) Double-reciprocal plot shows lines share the same x-intercept, suggesting 
Rabeprazole binds allosterically as a non-competitive inhibitor. *These experiments 
were performed by Dr. Deming Chau.  
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 Mutation of Recombinant Substrates Suggests P2 Cysteine of Notch is Binding Site 
for Benzimidazole Compounds 
 
 There are five cysteines in presenilin, three in nicastrin, three in Aph-1, one in 
Pen-2, and seven in the recombinant Notch (rNotch) substrate used in our assays. 
There are no cysteine residues in the recombinant APP used. Therefore, 
benzimidazoles could be binding to gamma-secretase, or the Notch substrate, or both. 
Interestingly, one of the cysteine residues, Cys-1752 in Notch, is located just two 
residues away from the scissile bond, at the P2 position according to common protease 
nomenclature [198] (Figure 4.7).  Furthermore, past studies in our lab have shown that 
substitution of this cysteine to other amino acids can result in changes to gamma-
secretase processing and specificity [166]. Therefore, we hypothesized that 
benzimidazoles could be binding to the P2 cysteine of Notch resulting in inhibited 
cleavage by gamma-secretase.  
 Figure 4.7: Schematic of the Notch substrate within the active site of 
gamma-secretase. According to Schechter and Berger nomenclature, residues to the 
right of the scissile bond are referred to as P1’, P2’, etc. and the corresponding enzyme 
subpockets S1’, S2’, etc. To the left of the cleavage site residues are designated P1, 
P2, etc. and enzyme subpockets S1, S2, etc.  
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In order to test our hypothesis, we generated a series of P2 rNotch mutants and 
tested them in an IC50 assay with a benzimidazole compound.  Mutation of the P2 
cysteine residue to any amino acid tested resulted in complete loss of gamma-secretase 
inhibition. Furthermore, if we re-introduce a cysteine at the P1 or P3 position on the 
P2 methionine rNotch mutant, we see nearly complete rescue of inhibition by 
benzimidazole. This data supports our hypothesis that benzimidazoles bind to the P2 
cysteine of rNotch to inhibit gamma-secretase cleavage.  
Figure 4.8: P2 cysteine of rNotch is vital for inhibition by benzimidazoles.                
A) Mutation of rNotch P2 cysteine to various amino acids results in loss of inhibition. 
B) Re-introduction of cysteine at P1 or P3 in P2 methionine mutant rescues inhibition 
by benzimidazoles.  
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Gamma-secretase cleaves APP at multiple positions within the transmembrane 
domain to release Aβ peptides of various lengths as well as the APP intracellular 
domain (AICD), which is synonymous to gamma-secretase cleavage of Notch to 
release NICD. APP contains a threonine residue at the P2 position, relative to AICD 
cleavage.  Benzimidazole compounds do not inhibit the production of wild type 
AICD, however, mutation of P2 threonine to cysteine, results in benzimidazole 
inhibition of AICD production (Figure 4.9), further supporting our hypothesis that 
benzimidazole binding to the P2 position of the substrate is sufficient to inhibit 
cleavage.  
Figure 4.9: Production of AICD from mutant P2C APP is inhibited by 
benzimidazoles, while there is no effect on cleavage of WT APP.   
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Labeling with Benzimidazole Based Probes Demonstrates Binding to Gamma-
Secretase on PS1-NTF, PSI-CTF and Pen-2 
 
Evidence of benzimidazoles binding to the Notch substrate does not eliminate 
the possibility that these compounds are also binding to gamma-secretase. In order to 
explore this possibility, we first utilized photoaffinity labeling (PAL) with 
benzimidazole based benzophenone probes. PAL has previously been shown to be a 
useful method for target identification [199], and has proven to be a valuable tool for 
the study of GSIs and GSMs in the past [31, 116, 117, 200, 201]. PAL utilizes the 
addition of a photoreactive group, such as a benzophenone, into the compound of 
interest to covalently capture the targets of small molecules. Biotin is often 
incorporated into the photoreactive probe as a means to isolate the labeled target; 
however, use of such a large group can often impair the inhibitory activity of a 
compound by reducing potency or limiting access to the site of action. Clickable 
photoaffinity probes have the advantage of using a much smaller chemical group, such 
as a terminal alkyne, that can be “clicked” to another reactive group, such as biotin-
azide, which facilitates enrichment with streptavidin (SAD) beads. A clickable, 
photoaffinity probe, PPI-BP, was designed based on the structure of Rabeprazole, has 
been synthesized and was shown to have similar activity and potency to that of the 
parent compound against NICD, Aβ40, and Aβ42 generation (Figure 4.10A,B). PPI-
BP was incubated with gamma-secretase containing HeLa membranes in the presence 
and absence of the parent compound, then UV irradiated to cross-link to nearby 
proteins. Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC), also called 
Azide-Alkyne Huisgen Cycloaddition, was utilized to click a biotin-azide group to the 
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probe, followed by capture with streptavidin beads and analysis by western blot using 
anti-bodies for each component of gamma-secretase. PS1-NTF was found to be 
robustly and specifically labeled by PPI-BP (Figure 4.10C). The other gamma-
secretase components tested were not labeled, but this does not necessarily rule out the 
possibility that PPIs interact with these components, as PAL is highly dependent on 
the proper orientation of probe in relation to nearby residues.    
Figure 4.10: Photoaffinity labeling with PPI-BP shows specific labeling of 
PS1-NTF in HeLa membranes. A) Chemical structure of PPI-BP B) One-pot IC50 
assay shows that PPI-BP potently inhibits NICD and increases production of Aβ42   
C) Photoaffinity labeling with PPI-BP (1μM) shows specific labeling of PS1-NTF that 
is blockable with 25μM parent compound. Note: Levels of Aph-1 in HeLa membranes 
are not sufficient for detection by western blot 
 
Because we believe that PPIs are binding their target via a disulfide bond, this 
represents a unique opportunity to use labeling techniques not available to compounds 
that non-covalently bind their target. It does, however, require the use of copper-free 
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click chemistry in order to maintain the bond between probe and target. We have 
synthesized a tetrazine probe, PPI-Tz, that is a potent gamma-secretase modulator and 
can be reacted with trans-cyclooctene conjugated to biotin or a reporter dye for target 
identification (Figure 4.11A,B). Additionally, rather than using HeLa membranes, we 
have utilized a HEK293 cell line that overexpresses each component of Gamma-
Secretase, to ensure that insufficient protein levels are not an issue. ANPP membranes 
were incubated with PPI-Tz, and copper-free click chemistry was utilized to attach a 
biotin tag. A streptavidin resin was then used to enrich for labeled proteins, followed 
by western blot analysis using primary antibodies for each gamma-secretase 
component. Again, we observe specific labeling of PS1-NTF, in addition to labeling of 
PS1-CTF and Pen-2. Because DTT is used in this experiment for blocking, this also 
indicates that benzimidazoles are covalently binding gamma-secretase sub-units by 
disulfide linkage.  
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Figure 4.11: Benzimidazole based tetrazine probe specifically labels PS1-
NTF, PS1-CTF and Pen-2. A) Chemical structure of PPI-Tz B) One-pot IC50 assay 
shows that PPI-Tz potently inhibits NICD and increases production of Aβ42 C) Direct 
labeling with PPI-Tz (1μM) demonstrates disulfide bond formation between 
benzimidazole probe and PS1-NTF, PS1-CTF and Pen-2, that is blockable with 50mM 
DTT. Input in the first lane is 5μg ANPP membrane.  
 
Fluorescent Labeling Shows Benzimidazoles Bind to PS1-NTF, PS1-CTF, Pen-2, and 
rNotch substrate 
 
To confirm these findings, we aimed to show specific labeling of gamma-
secretase through an additional method, as well as show specific labeling of the 
recombinant Notch substrate. Copper free click chemistry between PPI-Tz and trans-
cyclooctene-TAMRA was used to conjugate a fluorescent dye to benzimidazole 
targets in ANPP membranes. Consistent with the results of western blot analysis we 
see labeling of three proteins at approximately 30, 20, and 12 kDa, corresponding to 
PS1-NTF, PS1-CTF and Pen-2 respectively (Figure 4.12). Interestingly, the intensity 
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of fluorescent bands is increased with the addition of rNotch substrate, suggesting the 
formation of a stable enzyme-inhibitor-substrate triplex.  
Figure 4.12: TAMRA labeling with PPI-Tz (1μM) probe shows molecular 
targets of approximately 25kDa, 20kDa, and 12kDa in ANPP membrane. The addition 
of 50mM DTT demonstrates specificity and Coomassie staining confirms equivalent 
amounts of protein loaded in each lane.  
 
Furthermore, the rNotch substrate was robustly and specifically labeled, while 
the P2 methionine mutant was not (Figure 4.13). Additionally, no labeling was seen 
with the wild-type rAPP substrate, but was seen in the P2 cysteine rAPP mutant 
(Figure 4.13). This data coincides with our IC50 studies and further supports our 
hypothesis that the P2 cysteine of the Notch substrate is a binding site for 
benzimidazoles.  
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Figure 4.13: P2C in recombinant substrates is specifically labeled by PPI-
Tz and TAMRA. A) Wild type rNotch is specifically labeled by PPI-Tz, while the P2 
methionine mutant is not. Additionally, the mutant P2 cysteine rAPP is also 
specifically labeled. The addition of 50mM DTT shows specificity of labeling while 
silver stain for total protein confirms equivalent amounts of protein were added to 
each lane 
 
4.3 Discussion and Conclusions  
While all the data presented thus far provides strong evidence that 
benzimidazoles act through a similar mechanism to modulate gamma-secretase as they 
do inhibiting the proton pump, there is one important detail that must not be 
overlooked: all of our IC50 assays and labeling experiments are performed at an 
essentially neutral pH, so how are these compounds being activated to form disulfide 
bonds with gamma-secretase and rNotch? The pKa of the pyridine nitrogen is 4.53, 
and according to the Henderson-Hasslebach equation, at a pH near seven, less than 
0.1% of benzimidazole molecules will be protonated. Additionally, the pKa of the 
second nitrogen to be protonated in the activation cascade is 0.63, indicating that an 
even lower percentage of molecules will be protonated at this nitrogen under assay 
conditions. 
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We originally hypothesized the existence of an acidic microenvironment 
within the gamma-secretase complex where benzimidazoles could be activated before 
binding the rNotch P2 cysteine. The existence of an acidic pocket is not without 
precedent, as many aspartyl proteases such as pepsin, chymosin, cathepsin D, and 
nepenthesin have been reported to have highest enzymatic activity at pH’s ranging 
from 2.5 to 3.8[202-204]; although, a large body of current research suggests that the 
gamma-secretase active site is water accessible and that the optimal pH for cleavage is 
7 [112, 205, 206]. Furthermore, the TAMRA labeling experiments using recombinant 
substrates were performed in the absence of the gamma-secretase complex and we still 
observe labeling.  We think perhaps the local concentration of substrate and/or are 
high enough to react with the small fraction of activated benzimidazole molecules. In 
order to test this, we wanted to see if we see increased labeling in buffers with lower 
pH, where there should be a higher fraction of benzimidazole molecules activated. 
Indeed, if we perform the same labeling experiment using PPI-Tz and TAMRA with 
wild-type rNotch, we see an increase in labeling intensity with decrease in the pH of 
the buffer (Figure 4.14).  
Figure 4.14:  TAMRA labeling of WT rNotch is increased with decreasing pH.  
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 Another important caveat we must consider is the fact that we observe direct 
binding to rNotch, and modulation of APP processing. While we do have evidence 
that benzimidazoles are also directly binding to gamma-secretase, based on the 
location of the target Notch cysteine, so close to the scissile bond, it seems likely that 
Notch cleavage is being inhibited based solely on steric hinderance from the active site 
when bound to benzimidazole. Competition studies performed using our one-pot 
activity assay suggest that the two substrates compete for cleavage (Figure 4.15), so 
we hypothesized that the increase in Aβ production is due to increased availability of 
gamma-secretase active sites when Notch is blocked from binding. In support of this 
hypothesis, we’ve found that the increase in Aβ42 is eliminated when we assay 
benzimidazole IC50 with the P2 methionine rNotch mutant.  
Figure 4.15: Benzimidazole compounds do not increase Aβ42 when assayed with 
mutant P2 methionine rNotch in the one-pot gamma-secretase activity assay.  
 
In summary, we have discovered that benzimidazoles are novel modulators of 
gamma-secretase activity. They inhibit the production of NICD, while increasing 
production of Aβ peptides. Our studies strongly suggest that benzimidazoles bind to 
the P2 cysteine of the Notch substrate, as well as to cysteine residues in PS1-NTF, 
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PS1-CTF, and Pen-2. Further analysis using mass-spectrometry will confirm our 
findings (See Appendix A). How these compounds are being activated at a neutral pH 
remains to be elucidated, but we plan to utilize NMR analysis to determine exactly 
which species are present under our assay conditions. The increase in Aβ peptides 
observed with benzimidazole treatment may preclude these molecules from being used 
in the clinic, but this work demonstrates the possibility of a Notch specific inhibitor 
and provides important rationale for clinicians to use caution before indiscriminately 
prescribing proton pump inhibitors to patients.  
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CHAPTER 5: 
Benzimidazole Covalent Probes and the Gastric H+/K+-ATPase as a Model 
System for Protein Labeling in a Copper-free Setting
1
 
 
5.1 Background 
The discovery of benzimidazoles as novel gamma-secretase modulator presented 
an opportunity to utilize methods exclusive to working with covalent probes. The 
development of covalent enzyme inhibitors is often avoided due to concerns of 
selectivity and possible immunogenicity of enzyme-inhibitors adducts. This is 
unfortunate, as covalent inhibitors often have increased efficiency and duration of 
action and also unnecessary as the development of clickable covalent probes can allow 
researchers to determine possible off-target effects[207-209]. Some of the most 
successful therapeutics in history are covalent inhibitors. For example, aspirin works 
as an NSAID by irreversibly acetylating a serine residue in the active site of 
cyclooxygenase COX-1 and COX-2[210, 211].  
 
As detailed in Chapter 3, substituted benzimidazole compounds are covalent 
inhibitors widely used for the treatment of acid-related gastric diseases such as peptic 
ulcers and gastroesophageal reflux disease[212, 213]. Benzimidazole compounds are 
pro-drugs that must first undergo two protonations and a subsequent spontaneous 
rearrangement to become sufficiently reactive[194, 214]. Once activated, they form a 
disulfide bond with cysteine residues within the proton pump, the gastric H
+
/K
+
-
ATPase, resulting in irreversible inhibition of enzymatic activity[193, 215-218]. 
Because this reaction has been extensively studied and the target irrefutably identified 
70 
 
as the catalytic subunit of the H
+
/K
+
-ATPase [195, 218], ATP4A, covalent probes 
derived from these compounds can serve as a useful model system for testing the 
efficiency of different bioorthogonal reactions in protein labeling.  
 
The copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction has 
widespread use in bioorthogonal labeling; however, this type of reaction is not always 
ideal because it requires a copper catalyst. In the case of benzimidazoles, reducing 
agents disrupt the disulfide bond between inhibitor and enzyme making CuAAC 
unsuitable for protein labeling with these compounds. By incorporating clickable 
moieties compatible with copper-free click chemistries, one can utilize covalent 
probes without being limited by toxicity or solubility issues[219-221]. Subsequently, 
the strain-promoted azide-alkyne cycloaddition (SPAAC)[222, 223]
 
and inverse 
electron demand diels-Alder (iEDDA)[224-226] reaction for tetrazine ligation have 
become increasingly popular for protein labeling applications.  
 
We have synthesized a series of benzimidazole analogues containing different 
“clickable” moieties that can be used in a copper free setting to directly label the 
molecular target of these compounds: the H+/K+ exchanging ATPase or the gastric 
proton pump. We have directly compared tetrazine ligation and SPAAC and found 
that tetrazine ligation is far superior; not only in regard to reaction rate, but efficiency 
as well. Our results validate the development of chemical probes for discovery of 
unknown targets and also emphasize the ease of implementation when using copper-
71 
 
free clickable systems. In particular, this study highlights the utility and efficiency of 
tetrazine covalent probes.  
5.2 Results 
Benzimidazole Probes are Potent Proton-Pump Inhibitors 
We synthesized two benzimidazole probes, Rabe-Tz and Rabe-N3 
(Figure 5.1A). Tetrazines and trans-cyclooctenes undergo a rapid inverse-
demand Diels Alder reaction followed by a retro-Diels Alder reaction to 
eliminate nitrogen gas and can be used for bioconjugation at extremely low 
concentrations [227]. Conjugated dibenzocyclooctene reacts with terminal azide 
via strain promoted azide-alkyne cycloaddition in an alternate copper-free click 
reaction(Figure 5.1B) [222].  
Figure 5.1: Structures of synthesized benzimidazole probes and the 
corresponding copper-free click chemistries available to each.  
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  In order to determine if the synthesized analogues retain inhibitory 
activity against the proton pump, we prepared gastric H
+
/K
+
-ATPase containing 
vesicles for use in a colorimetric activity assay.  Differential centrifugation of 
gastric mucosa from pig stomachs, with slight modifications from procedures 
previously reported [228-230], was used for vesicle isolation (Figure 5.2A). To 
characterize the gastric H
+
/K
+
-ATPase in our sample, enzyme activity was 
detected by measuring the amount of inorganic phosphate released using the 
PiColorLock Gold Phosphate Detection System. Background phosphate release 
was measured using reactions carried out in the absence of MgCl2, in which 
gastric H
+
/K
+
-ATPase is inactive, as described previously by Shin et al[231].  
Gastric H
+
/K
+
-ATPase activity was defined by the difference in signal in the 
absence and the presence of 100 M Rabeprazole, a known proton-pump 
inhibitor (Figure 5.2B,C).  
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Figure 5.2: Benzimidazole probes inhibit gastric H+/K+-ATPase activity. 
A) Western blot analysis confirming the presence of the gastric H+/K+-ATPase, 
ATP4A, in isolated vesicles. B) Structure of known proton-pump inhibitor, 
Rabeprazole  C) Gastric H+/K+-ATPase activity is inhibited by 100μM 
Rabeprazole and D) benzimidazole probes inhibit ATPase activity by 
approximately 50% at 10μM compound.  
 
 
Each benzimidazole probe (10μM) was incubated with H+,K+-ATPase 
containing vesicles to determine their potency. Figure 5.2D shows the inhibitory 
activity of synthesized compounds in our assay. We tested both analogues in 
comparison to the known inhibitor, Rabeprazole, and found that all compounds 
tested inhibit the enzyme at similar levels. This suggests that the modifications 
to the core benzimidazole structure did not change potency of either compound.  
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Direct Labeling of Gastric H
+
/K
+
-ATPase, ATP4A, with Benzimidazole 
Analogues  
 
Since the analogues completely retained inhibitory activity, we tested if 
they still directly bind and label their target. Gastric H
+
/K
+
-ATPase containing 
membranes were prepared using differential centrifugation, incubated with each 
probe, and copper-free click chemistry (Figure 5.1B) was utilized to attach a 
biotin tag. A streptavidin resin is then used to enrich for labeled proteins, which 
can be analyzed using western blot (Figure 5.3A). Because these compounds 
require low pH for activation, labeling should only occur under sufficiently 
acidic conditions. We performed the labeling experiment using Rabe-Tz at a pH 
of 2, 3, 4 and 7 and observed labeling of a protein with apparent molecular 
weight of 270kDa at pH=3 (Figure 5.3B). While a recent study proposes that the 
active form of the ATPase is the monomeric form (≈114kDa)[230], extensive 
early research suggest the enzyme functions as a dimer or  higher oligomer in 
conjunction with the β subunit[232-237]. Our finding suggests that active 
ATP4A is a dimer.  Surprisingly, no labeled ATP4A was detected at pH 2, in 
which Rabe-Tz should be activated for covalently binding to the target.  We 
reasoned that ATP4A is less soluble when it was treated at pH 2 and extracted 
from the membrane environment. For this reason, all subsequent experiments 
were run at pH=3. Specificity of labeling was shown by addition of a reducing 
agent, used to break the disulfide bond between the probe and its target.  For 
both compounds, labeling is completely abolished by the addition of 50mM 
DTT (Figure 5.3C). Next, we directly compared the labeling efficiency of the 
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two analogues by titrating the dose of probe used for labeling between 0.3 and 
3.0 μM. As shown in Figure 5.3D, each compound labels ATP4A in a dose 
dependent manner, but Rabe-Tz is clearly more efficient, labeling with much 
stronger intensity at similar concentrations. 
 
 
Figure 5.3: Benzimidazole probes label the gastric H+/K+-ATPase, ATP4A. 
A) Schematic drawing of labeling protocol. After incubation of probe and 
gastric membranes biotin is “clicked” onto the probe, the target enriched using 
streptavidin beads, separated using SDS-PAGE and analyzed by western blot. 
B) Labeling is pH dependent, requiring a pH of 3.0 for acid activation of 
benzimidazole compounds. C) Direct comparison of labeling efficiency 
between probes at 1μM shows that labeling is blockable with DTT (50mM).   
D) Labeling with 0.3, 1, and 3μM probe shows that labeling is dose dependent 
and Rabe-Tz labels more efficiently than Rabe-N3 at equivalent concentrations.  
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 There are two possibilities that explain the differences in labeling 
efficiency between Rabe-Tz and Rabe-N3. The first possibility is that Rabe-Tz 
binds to the proton pump with a higher affinity. The second option is that 
tetrazine ligation is more efficient than SPAAC, resulting in superior labeling. 
Based on the activity data showing that each analogue inhibits the proton pump 
with similar potency, it is plausible to assume that Rabe-Tz labels more strongly 
due to a more efficient click reaction[238].  
   
Fluorescent Imaging of Labeled Proteins 
To take advantage of the efficient labeling of ATP4A with Rabe-Tz, we 
sought to identify Rabe-Tz labeled proteins using an unbiased approach: direct 
labeling with tetramethyl rhodamine (TAMRA) dye (Figure 5.4A).  Following 
incubation of gastric vesicles with the tetrazine probe, we clicked a trans-
cyclooctene-TAMRA dye to labeled proteins for visualization on SDS-PAGE 
gel. Figure 4B shows that Rabe-Tz directly labels two protein bands with 
apparent molecular weight of approximately 270 kDa and approximately 
70kDa.  Moreover, both bands are eliminated with the addition of DTT, and 
Coomassie blue staining confirms that equal amounts of protein were loaded to 
each lane (Figure 5.4B).  
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Figure 5.4: TAMRA labeling with Rabe-Tz. A) Schematic representation of 
protocol used for unbiased protein labeling with TAMRA dye. B) Rabe-Tz 
probe specifically labels protein at >250kDa  and approximately 70kDa. . Lane 
1 and 2 are duplicate samples while Lane 3 demonstrates that labeling is 
blocked by 50mM DTT.  
 
  In order to identify these TAMRA labeled proteins, we performed a pull 
down experiment based on the protocol shown in Figure 3A, however, 
following SDS-PAGE, we stained the gel with Coomassie blue. No clear bands 
were visible, so gel slices at approximately 250kDa and ~70 kDa, where 
TAMRA labeling was observed, were excised and digested for liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis.  Peptide 
identifications were accepted if they could be established at greater than 95% 
probability to achieve an FDR less than 1.0% by the Scaffold Local FDR 
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algorithm. Protein identifications were accepted if they contained at least 4 
identified peptides.  
Table 5.1. Proteins identified by MS analysis of Rabe-Tz pull down 
 
The band at 70kDa was found to correspond to serum albumin and is 
likely pulled down as a result of its extremely high abundance.  For the higher 
molecular weight band, five proteins were identified exclusively in the sample 
not treated with DTT and can be seen in Table 5.1. As expected, the catalytic 
subunit of the gastric H
+
/K
+
-ATPase was a top hit, further confirming ATP4A 
as the target of Rabe-Tz.  In addition, Isoform 2 of deleted in malignant brain 
tumors 1 protein (DMBT1) was also identified. This protein is a secreted 
scavenger receptor cysteine-rich protein that has been reported to be deleted in 
numerous human cancers including: brain[239], lung[240], and gastrointestinal 
cancers[241]. It is thought to play a role in both immune defense and epithelial 
differentiation[242] and has also been reported to bind Helicobacter pylori[243]. 
Interestingly, Benzimidazole compounds are commonly used to treat H.pylori 
infection[244] with an unknown cellular target and both DMBT1 and 
benzimidazole compounds have been reported to play a protective role for 
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gastrointestinal mucosa[245, 246]. It would be interesting to carry out more 
studies to examine the physiological interaction between DMBT1 and 
benzimidazole compounds.   
 
Alternatively, the abundance of cysteine residues in this protein could 
account for benzimidazole binding under low pH.  The remaining three proteins 
are currently uncharacterized in the literature, although, according to 
www.uniport.org, F1SKJ1 is inferred to have actin-dependent ATPase activity 
based on electronic annotation through Ensembl. Whether our probes bind to 
these proteins due to unrecognized ATPase activity or whether they only bind 
benzimidazoles under artificially low pH remains to be investigated.  
5.3 Discussion and Conclusions 
We have synthesized two benzimidazole based probes and shown that 
both specifically label the catalytic component of the gastric H
+
/K
+
-ATPase, 
ATP4A. By directly comparing protein labeling using tetrazine ligation and 
SPAAC, we have demonstrated that tetrazine ligation is more useful; not only is 
tetrazine ligation faster, it is also more efficient. If tetrazine modification is 
tolerated on compounds of interest, we recommend this as the preferred 
approach for copper-free bio-orthogonal reactions. 
 
Moreover, MS analysis of proteins targeted by benzimidazole probes 
confirm the use of  covalent probes for target identification, as well as revealed 
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a potential link between benzimidazole compounds and DMBT1 for H. pylori 
eradication and mucosal protection.   
 
5.4 Detailed methods  
Compound Synthesis 
Benzimidazole probes were synthesized by Dr. Qi Liu as previously 
reported[247]. 
Preparation of Porcine Gastric H+/K+-ATPase Enzyme  
Gastric H+/K+-ATPase was isolated using a protocol adapted from Dach et al. 
2012[230] and Skrabanka et al 1984[229]. Fresh porcine stomachs were obtained from 
Innovative Research Inc (Novi, MI) and kept on ice during each step.  Gastric mucosa 
was scraped from the stomachs with a cell scraper and homogenized 1:1 v/v in 
homogenization buffer (0.25M Sucrose, 20mM TRIS-HCl, pH=7.4) using an 
immersion blender. The mucosa was further homogenized with 8 passes of piston-
based motorized homogenizer.  The sample was centrifuged at 27,000g (17,235rpm) 
for 20 minutes in a Sorval T-1250 rotor.  The supernatant was transferred to a clean 
tube and re-centrifuged at 100,000g (33,000rpm in Sorval T-1250) for 1 hour. The 
pellet was re-suspended in homogenization buffer, homogenized with 5 passes of the 
motorized homogenizer and layered on a two-step gradient consisting of 37% sucrose 
(w/v) and 20 mM Tris-HCl (pH 7.4) at the bottom with 7% Ficoll at the top (GE 
Healthcare), 0.25 M sucrose, and 20 mM Tris-HCl (pH 7.4). The sample was 
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centrifuged at 217,000g (35,000rpm in Thermo Scientific TH-641 rotor) for 1 hour 
H
+
/K
+
-ATPase containing vesicles were collected from the top of the ficoll layer and 
diluted with 20mM Tris buffer (pH=7.4) and centrifuged at 217,000g (49,000rpm in 
Sorval T-1250) for 30minutes. The pellet containing the vesicles was re-suspended in 
20mM Tris (pH=7.4) and kept frozen in small aliquots at -20°C for short term and -
80°C for long term storage. 
Gastric H
+
/K
+
-ATPase Activity Assay 
Isolated vesicles (15ug/mL) were pre-incubated for 15 minutes at 37°C with 
compound or vehicle in assay buffer (20mM TRIS-HCl, (pH=7), 10mM KCl, 2mM 
MgCl2) in the presence of 1ug/mL nigericin. The gastric H+/K+-ATPase was activated 
by the addition of 2mM NaATP (Sigma) and incubated at 37°C for 45 minutes. 
Activity was determined by measuring inorganic phosphate release using the 
PiColorLock Gold Phosphate Detection System (Innova Biosciences, Cambridge, 
UK). Assay background was measured by carrying out reactions in the absence of 
vesicles; while background phosphate release was measured using reactions carried 
out in the absence of MgCl2 Reactions without compounds were run with vehicle, 
DMSO, as a positive control. The following equations were used to calculate potency 
of inhibition:  
𝑩𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅 = 𝑆𝑖𝑔𝑛𝑎𝑙 𝑎𝑡 100𝑢𝑀 𝑅𝑎𝑏𝑒𝑝𝑟𝑎𝑧𝑜𝑙𝑒 
𝜹 = 𝑆𝑖𝑔𝑛𝑎𝑙 − 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 
%𝑨𝒄𝒊𝒕𝒊𝒗𝒊𝒕𝒚 𝑹𝒆𝒎𝒂𝒊𝒏𝒊𝒏𝒈 =   
𝛿𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝛿𝐷𝑀𝑆𝑂
 𝑋 100 
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Preparation of Gastric Mucosa Membranes 
Fresh porcine stomachs were obtained from Innovative Research Inc (Novi, 
MI) and kept on ice during each step.  Gastric mucosa was scraped from the stomachs 
with a cell scraper and homogenized 1:1 v/v in buffer A (50 mM MES, pH 6.0, 5 mM 
MgCl2, 5 mM CaCl2, 150 mM KCl) using an immersion blender. The mucosa was 
further homogenized with 10 passes of a piston-based motorized homogenizer.  The 
homogenate was centrifuged at 800g for 10 minutes to remove cell debris and nuclei. 
The supernatant was centrifuged at 100,000g for 1 hour at 4°C. The pellet was 
resuspended in buffer A and the centrifugation at 100,000g repeated.  The final 
membrane pellet was resuspended and homogenized in buffer A to a final 
concentration of approximately 18mg/mL and stored at -80°C.  
 
Labeling of Mucosa Membrane with Benzimidazole Probes and Western Blot Analysis 
Membrane fractions containing endogenous H
+
/K
+
-ATPase were isolated from 
porcine gastric mucosa using ultracentrifugation methods described above. Isolated 
membrane (800ug) was incubated with each benzimidazole analogue (1uM) in a 
glycine buffer at pH=3 for 1 hour at 37°C while shaking. After incubation, copper free 
click reactions were initiated by adding Dibenzocyclooctene-PEG4-biotin (Sigma) 
(100uM) to reactions with Rabe-N3 and trans-cyclooctene-biotin, (16uM) to reactions 
with Rabe-Tz.  Reaction with either handle allows for conjugation of biotin to labeled 
proteins for pull down. Click reactions were allowed to proceed for three hours at 
room temperature. Reactions were centrifuged at 90,000g for 40 min at 4°C. 
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Supernatants were aspirated, thus removing excess click reagents. The pellets were 
resuspended by homogenization with a TissueLyser (Qiagen)  at 25 rps for 2 min and 
solubilized in RIPA buffer (50 mM Tris (pH= 8), 150 mM NaCl, 0.1% SDS, 1% 
NP40, 0.5% deoxycholate) then centrifuged at 12,000 rpm to remove particulate 
matter. To show blocking of labeling, 50mM DTT was added to select samples and 
incubated for 5 minutes at RT.  Streptavidin ultralink resin slurry (Pierce) was added 
to all supernatants and incubated overnight at 4C. Streptavidin resins were washed 4 
times by centrifugation at 0.5g followed by aspiration of supernatant and addition of  
500μL RIPA buffer. Labeled proteins were eluted by incubation with excess biotin 
(2mM) in 2X Laemmli sample buffer (Biorad) at 70°C for 10min. Eluates were loaded 
onto a precast 4–15% Criterion™ Tris-HCl gel (BioRad) for protein separation, 
transferred to a PVDF membrane and blotted for the H,K-ATPase with Anti-ATP4A 
antibody (ab174293) (AbCam). 
Fluorescent Labeling 
Benzimidazole probe, Rabe-Tz (2uM), was incubated with 150ug of gastric 
vesicles (preparation described above) in Glycine buffer (pH=3) for 1h at 37°C in the 
presence or absence of 50mM DTT or TCEP. Targeted proteins were labeled with 
tetramethyl rhodamine via spontaneous reaction of trans-cyclooctene-TAMRA 
(16uM) and the tetrazine present on Rabe-Tz for 1 hr at room temperature in the dark. 
Labeled proteins were then precipitated with 1mL of cold acetone at -20°C for 2 
hours, washed once with 500μL ammonium bicarbonate (100mM), then again with 
500μL cold acetone. Precipitated proteins were centrifuged at 15,000g for 10 min, the 
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acetone was removed, and the protein pellet was air-dried for 10 min. Protein pellets 
were resolubilized in 45μL PBS + 15μL 4x Laemmli Sample buffer (BioRad) while 
rotating at RT for 2 h. Lowry assay was used for total protein quantification and 25ug 
of each sample was loaded onto an SDS-PAGE gel for band separation and then 
scanned for fluorescent bands. The same gel was then immediately stained with 
Coomassie blue (BioRad) to compare the total amount of protein in each sample.  
Pull down with Rabe-Tz for LC- MS/MS Analysis 
The protocol described for “Labeling of Mucosa Membrane with 
Benzimidazole Probes” was followed using Rabe-Tz (1uM) and trans-cyclooctene-
biotin (16uM) with the exception that the click reaction was only allowed to proceed 
for 1 hour. Following protein separation by SDS-PAGE protein bands of interest were 
excised, destained and SDS removed by washes with 50% methanol (v/v).  These gel 
pieces were then dried using a speed-vac.  To reduce the disulfide bonds, 10 mM DTT 
in 25 mM ammonium bicarbonate was added until the pieces were covered with 10 
mM DTT in 25 mM ammonium bicarbonate for 1 hour at 56°C.  For alkylation, the 
reducing agent was removed and the gel pieces were covered with freshly made 55 
mM iodoacetamide in 25 mM ammonium bicarbonate at room temperature in the 
dark.  After 45 minutes, the supernatant was removed and gel pieces were rinsed with 
100 mM ammonium bicarbonate three times.  Gel pieces were again dried using a 
speed-vac.  To dried, gel-bound protein, 200 ng of trypsin (modified, sequencing 
grade, Promega) in 10 μl of 100 mM ammonium bicarbonate was added to swell the 
gel piece.  Then an additional 90 μl of 100 mM ammonium bicarbonate was added or 
85 
 
until the gel piece was covered with the digestion solution.  Tryptic digestion was 
allowed to proceed at 37°C overnight.  The supernatant containing the generated 
peptides was removed and desalted using Poros R2 beads as described in Erdjument-
Bromage et al (1998).  Peptides were eluted with 3 μl of 40% (v/v) acetonitrile 
containing 0.1% (v/v) formic acid and stored at -20°C if not analyzed immediately.  
The purified peptides were diluted to 0.1% formic acid and each gel section 
was analyzed separately by microcapillary liquid chromatography with tandem mass 
spectrometry using the NanoAcquity (Waters) with a 100-μm-inner-diameter × 10-cm-
length C18 column (1.7 um BEH130, Waters) configured with a 180-um x 2-cm trap 
column coupled to an OrbiElite mass spectrometer(Thermo Fisher Scientific) scanning 
300-1650 m/z at 120000 resolution with AGC set at 1 x 10(6). Peptides were eluted 
with a linear gradient of 0-50% acetonitrile (0.1% formic acid) in water (0.1% formic 
acid) over 90 mins with a flow rate of 300nL/min.   Key parameters for the data 
dependent MS were top 10 DDA, AGC 1e4, and CID ms/ms collected in the linear ion 
trap.  
Database searching 
 Tandem mass spectra were extracted by ProteoWizard version 3.0.7529 from 
the raw files. Charge state deconvolution and deisotoping were not performed. All 
MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 
2.3.02) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). 
Mascot was set up to search the uniprot_pig_20150721 database (selected for 
Mammalia, unknown version, 26153 entries) assuming the digestion enzyme trypsin. 
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X! Tandem was set up to search a subset of the uniprot_sprot_20150223 database also 
assuming trypsin. Mascot and X! Tandem were searched with a fragment ion mass 
tolerance of 0.80 Da and a parent ion tolerance of 10.0 PPM. Carbamidomethyl of 
cysteine was specified in Mascot and X! Tandem as a fixed modification. Deamidation 
of asparagine and glutamine, oxidation of methionine, acetyl of the n-terminus and 
phospho of serine, threonine and tyrosine were specified in Mascot as variable 
modifications. Glu->pyro-Glu of the n-terminus, ammonia-loss of the n-terminus, gln-
>pyro-Glu of the n-terminus, deamidated of asparagine and glutamine, oxidation of 
methionine, acetyl of the n-terminus, carbamidomethyl of cysteine and phospho of 
serine, threonine and tyrosine were specified in X! Tandem as variable modifications.  
Criteria for Protein Identification   
Scaffold (version Scaffold_4.4.3, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 95% 
probability to achieve an FDR less than 1.0% by the Scaffold Local FDR algorithm. 
Protein identifications were accepted if they could be established at greater than 99.9% 
probability to achieve an FDR less than 1.0% and contained at least 4 identified 
peptides.  Protein probabilities were assigned by the Protein Prophet algorithm 
(Nesvizhskii, Al et al Anal. Chem. 2003;75(17):4646-58). Proteins that contained 
similar peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide 
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evidence were grouped into clusters. Proteins were annotated with GO terms from 
NCBI (downloaded Jul 22, 2015). (Ashburner, M et al Nat. Genet. 2000;25(1):25-9). 
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CHAPTER 6 
Thesis Summary and Major Implications 
 
We have successfully developed and utilized an efficient and applicable in 
vitro one-pot assay for measurement of gamma-secretase activity against APP and 
Notch simultaneously.  This assay has provided important insight into the enzyme 
kinetics of in vitro gamma-secretase activity and provides evidence for direct 
competition between Notch and APP for gamma-secretase cleavage at sufficiently 
high concentrations. Not only have we have shown that this assay can be used to 
screen for novel gamma-secretase modulators, but it also demonstrates the importance 
of using assays with both substrates present in order to accurately calculate selectivity 
margins. The widespread failure of gamma-secretase inhibitors in the clinic thus far, 
makes it clear that more stringent testing is necessary before compounds advance past 
pre-clinical trials. Use of our assay has the potential to save researchers valuable time 
and money by accurately determining selectivity for APP or Notch from the early 
stages of drug development.  
The fact that we observe a shift in selectivity for only certain compounds when 
compared between our one-pot and two-pot assay is intriguing and we are eager to 
determine the mechanism. Furthermore, it’s interesting that we observe this 
phenomenon with both a Notch targeted compound, LY-450,139, and an Aβ42 
targeted compound, GSM-1. The binding sight of GSM-1 has been shown to be PS-
NTF, but the binding site of LY-450,139 remains to be elucidated. It would be 
interesting to see if the two compounds have overlapping binding sites. We could 
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perform photoaffinity labeling with GSM-1 based probes and see if LY-450,139 is 
able to block labeling in order to determine if a similar binding site is the reason for 
similar behavior in our one-pot versus two-pot assay.  
While similar binding sites could explain why we see the same phenomenon 
with two distinct chemotypes, it still does not explain the mechanism for a shift in 
selectivity in the one-pot assay. Our prevailing hypothesis is that different GSIs and 
GSMs are actually targeting different gamma-secretase enzymes. As mentioned 
previously in the introduction, both Aph-1 and PS exist as multiple isoforms, allowing 
for the formation of six distinct complexes. Furthermore, an increase in PS2 
containing complexes has been shown to be positively correlated with increased 
Aβ42:Aβ40 ratios [51], demonstrating differential processing of APP by distinct 
gamma-secretase complexes.  Perhaps the compounds that experience a selectivity 
shift are actually binding to Aph-1a containing compounds, while compounds that do 
not experience a shift bind to Aph-1b containing compounds, or vice versa. Isoform 
dependent substrate selectivity has been observed, suggesting that each isoform of 
Aph-1 may contain unique substrate docking sites. Perhaps the addition of the 
alternate substrate only effects compounds that target Aph-1a because the substrate 
binds to a docking site resulting in a conformational change that alters active site 
structure or binding site structure and changes the potency for the other gamma-
secretase products. In order to test this, one could overexpress different complexes in 
separate cell lines, isolate gamma-secretase containing membranes and compare 
compound IC50 in the one-pot and two-pot assays.  Alternatively, you could use 
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CRISPR to selectively knock out a certain isoform and test the effect of compound 
IC50 in this model. 
It’s important to note that the loss in selectivity is not due to a loss in potency 
for inhibiting the production of the targeted species, but rather is due to an increase in 
potency for inhibiting the production of the off-target species. Another possible, but 
unlikely explanation is that the increase in potency for the off-target species is due to a 
decrease in available enzyme as a result of the inhibitor “locking” the enzyme in place 
the alternate substrate. This is not probable, as the IC50 of our compounds should not 
vary this drastically with subtle changes in enzyme concentration, but may be worth 
looking into. We could begin by testing the effect of lower enzyme concentration on 
the IC50 of these compounds. If we see a change similar to the magnitude that we see 
when comparing our one-pot to two-pot assay, we could continue on to pull-down 
experiments to further study enzyme-inhibitor-substrate interactions.  
It would also be interesting to see if the IC50 of GSIs and GSMs differ for 
gamma-secretase complexes isolated from different regions of the brain, specifically 
disease relevant tissues such as the hippocampus or tissues where Notch plays a tumor 
suppressor role such as the skin. PS1 and PS2 have both been shown to be expressed 
in neurons, glial cells and astrocytes, but are enriched in neurons of the hippocampal 
formation and entorhinal cortex [257].  Differential expression of accessory proteins in 
different tissues could also play a role in gamma-secretase activity and susceptibility 
to modulation by various compounds.  
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Our one-pot assay was used extensively in determining the mechanism of 
action of benzimidazole modulation of gamma-secretase activity. All of our data thus 
far suggests that these compounds are binding to an acidic pocket within gamma-
secretase, and being activated to form disulfide bonds with nearby cysteine residues 
within the Notch substrate as well as several components of gamma-secretase, similar 
to their activity on the gastric proton-pump.  
 In the future, we plan to confirm our findings from labeling experiments by 
using LC-MS to show direct binding of benzimidazoles to a synthetic Notch peptide as 
well as the identified components of gamma-secretase: PS-NTF, PS-CTF, and PEN-2. 
Additionally, we are able to circumvent the inherent difficulty of crystallizing 
complex membrane proteins by using a combination of photoaffinity labeling and 
proteomics to determine the exact binding site of these compounds. We will use a 
benzophenone containing probe to covalently modify benzimidazole targets through 
UV cross-linking and then identify the exact targeted cysteine residues using LC-MS. 
Use of the benzophenone allows us to overcome any limitations due to the reducibility 
of a disulfide bond. The most recent atomic structure of gamma-secretase, published 
in Nature by Bai et. al., will provide valuable insight into the positioning of these 
cysteine residues at the interface of presenilin and pen-2. 
Although our current model is plausible, as it’s been shown in several 
instances in the past that the local chemical environment of an enzyme active site is 
sufficient to drastically change pKa, it would also be interesting to test if the lipid 
composition of our sample is sufficient to affect the pKa as well. We could test this by 
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determining the pKa’s of relevant nitrogen’s in the presence of various lipids using 
UV spectroscopy or NMR.  
The fact that we observe a selective increase in the production of Aβ, most 
dramatically the production of Aβ42, suggests that direct binding to the P2 cysteine of 
Notch is not the only mechanism of action, and supports our hypothesis stated above. 
Moving forward, it will be important to ensure that the observed increase in Aβ is not 
due to any artifact of our assay conditions (ie. an increase in available acceptor or 
donor beads concurrent with a decrease in detectable NICD). In order to test this, we 
will need to assay the effect of benzimidazoles on gamma-secretase activity using 
another method. For example, detecting gamma-secretase products using mass-
spectrometry could provide an alternative method and could also be used to test the 
effect of benzimidazoles on the production of other Aβ peptides such as Aβ37, 43, 46 
etc.  
The implications of our findings merit immediate consideration granted the 
fact that Americans filled more than 170 million prescriptions for acid blockers last 
year, falling only behind statins in total cost expenditure worldwide (IMS Health, U.S. 
Pharmaceutical Market Performance Review™ 2015) and PPIs constitute the majority 
of this class. Recent epidemiological studies have reported an increased risk of 
dementia in elderly patients using proton-pump inhibitors [248, 249], which can be 
explained by the findings in our lab and others [197] that benzimidazoles increase Aβ 
peptide production. Even more concerning is the fact that the aggregate prone Aβ42 is 
the most strongly effected species.  Considering the fact that these compounds have 
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been shown to pass the blood brain barrier and exert effects on brain tissue [250], 
these findings are extremely concerning. Additional studies have reported a 
significantly higher risk of heart attack in PPI users compared to those on other 
antacid medication [251, 252], which could also be potentially explained by PPI 
inhibition of Notch cleavage by gamma-secretase. Not only is Notch signaling vital for 
proper heart development, but it has also been shown to play a role in adult cardiac 
repair [253] and long-term inhibition of Notch signaling in cardiac tissues has been 
postulated to cause cardiomyocyte and endothelial dysfunction [254]. 
Our work using benzimidazole based covalent probes, has also brought forth 
several important findings. First, this study validates the use of chemical probes for 
target identification, as our tetrazine probe successfully pulled down the known target 
of PPIs, the gastric proton pump. Second, we have demonstrated the superior 
efficiency of working with tetrazine probes when copper-free click chemistry is 
required and suggest their use whenever tolerated on compounds of interest. Lastly, 
we have identified several novel binding partners of benzimidazole probes, including 
Isoform 2 of deleted in malignant brain tumors 1 protein (DMBT1), which has been 
reported to bind H. pylori and could potentially provide a link between benzimidazole 
use and the eradication of H. pylori infection.  
The one-pot assay has also been utilized in two additional studies of GSIs and 
GSMs that are presented in Appendices B and C. Further discovery and development 
of Notch-specific gamma-secretase inhibitors is a key step in using gamma-secretase 
as a drug target to successfully treat Notch addicted cancers.  
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APPENDIX A: Preliminary LC-MS Analysis of Benzimidazole-Notch Adduct Formation 
The most straightforward, and arguably the most convincing, evidence for 
target identification is the detection of a drug-target adducts using tandem liquid 
chromatography - mass spectrometry (LC-MS). Figure A.1 shows the predicted 
weight of the benzimidazole-Notch adduct. We have generated a small synthetic 
peptide based on the sequence of Notch1 and observe a mass/charge (m/z) ratio of 
3700 when analyzed by LC-MS, based on the charged states of the ions present in the 
spectra (Figure A.2).  While the optimal conditions  for analysis remain to be 
determined, preliminary data shows the presence of the predicted benzimidazole-
Notch peptide adduct at 4042 in panel C of figure A.3. Unreacted/unbound 
benzimidazole and peptide are seen at Peaks A and D respectively.  Panel B shows an 
additional, unidentified species. It is important to note that we also observe a species 
at 342.2 when Rabeprazole is analyzed by itself that we believe corresponds to the lost 
of a water molecule (Figure A.4). 
Figure A.1: Predicted m/z for benzimidazole-Notch peptide adduct 
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Figure A.2: LC-MS analysis of synthetic Notch1 peptide (250pmol) 
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Figure A.3: LC-MS analysis of Rabeprazole (250pmol) incubated with 
synthetic Notch1 peptide (250pmol) for 1 hour prior to injection into LC-MS. 
Compound and peptide were both dissolved in DMSO.  
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      Figure A.4. LC-MS analysis of Rabeprazole (250pmol). 
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APPENDIX B: SPECS compound screen 
In an effort to discover novel Notch-specific gamma-secretase inhibitors, we 
have collaborated with SPECS (The Netherlands). Dr. Deming Chau directed the 
initial high-throughput screen and Dr. Qi Liu synthesized various analogues. I have 
followed up with an extensive structure-activity relationship analysis as detailed 
below.  
 More than 80 compounds were tested in our one-pot in vitro gamma-secretase 
assay (Table B.1) (See Chapter 2 for detailed methods). Compounds were originally 
screened at 2.5, 5 and 10μM.  IC50 values and selectivity margins were calculated for 
the most promising compounds (Table B.2).   
 The compound below served as our lead compound and was used as a starting 
point for designing and comparing analogues. It has an IC50 value of approximately 
1μM and is roughly 30x selective.  
 
 
 
Figure B.1. Lead compound in SPECS screen for Notch selective inhibitors  
In summary, we’ve found that the free amine of the thiophene is absolutely 
required for selective inhibition of Notch cleavage. Five, six, seven and eight 
membered-rings attached to the thiophene are tolerated, and the potency and 
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selectivity of MSK-49 demonstrates that the ring is not required for activity, although 
it is worth noting that MSK-51 does not inhibit NICD production. A wide range of 
substitutions are allowable on the benzene ring, including complete substitution to a 
pyridine ring with the nitrogen at the para, meta, or ortho positions. Adding an extra 
carbon between the amide and the benzene increases potency approximately 2-fold 
and increases selectivity to nearly 40x, as demonstrated with one of the most 
promising compounds, MSK-50. 
 
 Table B.1. Results of in vitro gamma-secretase assay for each SPECS 
compound. The requirement for being considered an inhibitor of NICD in second 
column was IC50<10μM. For IC50 assays, normalized AlphaLISA signals were converted 
to percent vehicle values and used to create dose-response curves which were fitted to 3 
parameter curves using GraphPad Prism version 6 (GraphPad Software, San Diego, CA).  
Selectivity margins were calculated by dividing Aβ40 IC50 by NICD IC50. Selectivity 
for compounds with * in notes column were calculated assuming IC50 for Aβ40=25. 
Compounds with ** assume Aβ40 IC50=100. Five-fold difference in NICD IC50  
compared to Aβ40 required to be considered selective.  
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Table B.1. Results of in vitro gamma-secretase assay for each SPECS 
compound. (Continued) 
 
 
 
Table B.1. Results of in vitro gamma-secretase assay for each SPECS 
compound. (Continued) 
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Table B.2. Chemical structures of screened SPECS compounds 
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Table B.2. Chemical structures of screened SPECS compounds (continued) 
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Table B.2. Chemical structures of screened SPECS compounds (continued) 
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Table B.2. Chemical structures of screened SPECS compounds (continued) 
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When the most potent compounds from our screen were tested in our cell-
based gamma-secretase assay, we did not detect any inhibition of Notch cleavage 
(Figure B.2). We hypothesize that this may be due to ionization of the free amine 
under physiological conditions. Potential “pro-drug” analogues that mask the free 
amine are currently under development.  
Figure B.2: SPECS compounds tested in cell-based gamma-secretase assay 
for Notch cleavage. None of the analogues tested exhibit NICD inhibition in cells. 
DMSO is the vehicle and used as a positive control, JC2, a  potent gamma-secretase 
inhibitor used as a negative control.  
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APPENDIX C: GSI-34 Optimization 
GSI-34 is a potent gamma-secretase inhibitor commonly used in the laboratory 
to investigate enzyme function[255]. It has also been shown to sensitize human colon 
adenocarcinoma cell lines to chemotherapy and was found to be synergistic with 
oxaliplatin, 5-FU, and SN-38 in an assay for cell viability [256]. Furthermore, GSI-34 
effectively blocks migration and invasion of aggressive breast cancer lines and 
reduced primary tumor burden and lung metastasis in a breast cancer mouse 
model[61].  In an effort to further develop the sulfonamide GSI for use a potential 
cancer therapeutic we have generated a series of GSI-34 analogues and tested their 
potency in our one-pot in vitro gamma-secretase activity assay. The most promising 
compound, C21, was tested in our cellular gamma-secretase assay, but was not as 
effective as GSI-34 treatment (Figure C.1).  
 
 
 
 
 
 
Figure C.1: Cell-based gamma-secretase activity assay. Treatment with the lead 
compound, C21, is not as effective as treatment with GSI-34.  
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Table C.1: Summary of in vitro gamma-secretase assay data for GSI-34 analogues. 
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